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ABSTRACT 
Breast cancer is the most common cancer and currently the second leading 
cause of death among women in the United States. Patients’ five-year relative 
survival rate decreases from 99% to 25% when breast cancer is diagnosed late. 
Immune checkpoint blockage has shown to be a promising therapy to improve 
patients’ outcome in many other cancers. However, due to the lack of early 
diagnosis, the treatment is normally given in the later stages. An early diagnosis 
system for breast cancer could potentially revolutionize current treatment 
strategies, improve patients’ outcomes and even eradicate the disease. The current 
breast cancer diagnostic methods cannot meet this demand. A simple, effective, 
noninvasive and inexpensive early diagnostic technology is needed. 
Immunosignature technology leverages the power of the immune system to find 
cancer early. Antibodies targeting tumor antigens in the blood are probed on a 
high-throughput random peptide array and generate a specific binding pattern 
called the immunosignature.  
In this dissertation, I propose a scenario for using immunosignature 
technology to detect breast cancer early and to implement an early treatment 
strategy by using the PD-L1 immune checkpoint inhibitor. I develop a 
methodology to describe the early diagnosis and treatment of breast cancer in a 
FVB/N neuN breast cancer mouse model. By comparing FVB/N neuN transgenic 
mice and age-matched wild type controls, I have found and validated specific 
immunosignatures at multiple time points before tumors are palpable. 
Immunosignatures change along with tumor development. Using a late-stage 
 ii 
immunosignature to predict early samples, or vice versa, cannot achieve high 
prediction performance. By using the immunosignature of early breast cancer, I 
show that at the time of diagnosis, early treatment with the checkpoint blockade, 
anti-PD-L1, inhibits tumor growth in FVB/N neuN transgenic mouse model. The 
mRNA analysis of the PD-L1 level in mice mammary glands suggests that it is 
more effective to have treatment early.  
Novel discoveries are changing understanding of breast cancer and 
improving strategies in clinical treatment. Researchers and healthcare 
professionals are actively working in the early diagnosis and early treatment fields. 
This dissertation provides a step along the road for better diagnosis and treatment 
of breast cancer. 
  
 iii 
DEDICATION 
  
I dedicate this dissertation to my wife Xinyao for her unconditional love and 
support, and my parents who accompany and help me during these days 
And 
To my son Roger who is the best gift for me before my graduation 
 
  
 iv 
ACKNOWLEDGEMENTS 
 
Six years of my PhD studies have led to this dissertation. I have 
experienced a lot during these years, and many people have influenced me 
positively. I want to offer my most sincere thanks to all the people who helped 
make me who I have become during these six years.  
Special thanks to my advisor, Dr. Stephen Albert Johnston. Dr. Johnston 
has inspired me and patiently taught me the most during my PhD studies. When I 
faced a complex problem, he always inspired and guided me to break it into small 
steps and push my thoughts further. One of his favorite expressions is “Keep it 
simple, stupid”—the KISS principle—I cannot tell express how much I benefited 
from this advice. I also learned a very important way to make decisions when the 
choices are controversial. Dr. Johnston fully supported me in my dissertation 
project through both his efforts to prepare me intellectually and his willingness to 
offer me specific scientific advice. Dr. Leland Hartwell has been more than a 
committee member for me. Besides his insightful comments on my dissertation, 
what I learned most came from his spirit. His constant eagerness to learn 
knowledge in a new field, his integrity and his modesty set an excellent example 
for me to follow. I have also consulted with him on my career development and 
shared many thoughts about my life and dreams. Dr. Hartwell always encouraged 
and advised me, which made me more confident in pursuing my dream. Every 
time I talked with Dr. Valentin Dinu, he provided me with new knowledge on 
bioinformatics analysis. Although Dr. Dinu was mainly at the Mayo Clinic, and it 
was a long way for him to come to Biodesign, he was always very willing to meet 
 v 
me with great patience and kindness. I learned immunology from Dr. Yung Chang 
when I took her classes in 2010. I would like to thank her for sharing her 
knowledge of immunology and for supporting my dissertation project.  
I also want to thank Dr. Kathy Sykes, Dr. Sid Hecht and Dr. Tim Karr, 
who were on my comprehensive exam committee. They helped and supported me 
in becoming a PhD candidate. During my PhD studies, it was a pleasure to work 
with the people in the Center for Innovations in Medicine in the Biodesign 
Institute at ASU. I am grateful to be a member of the Biological Design Graduate 
Program, which provides funding to support me. I thank Dr. Joann Williams, 
Maria Hanlin, Laura Hawes and Lauren Dempsey, who guided me in each step 
toward graduation and provided managerial support for my PhD program.  
With regard to my dissertation studies, I would like to specially thank the 
following individuals. Dr. Luhui Shen was the major collaborator in my 
dissertation project. Dr. Bart Legutki was my first guide when I did my rotation in 
CIM back in 2009. John Lainson taught me a lot about microarray production and 
automatic robot systems, and we had many amusing talks that made life at CIM 
more interesting. I shared an office with Dr. Josh Richer for two years, and we 
spent quite a lot time together discussing each other’s experiment. The many 
arrays that were run in the past six years would not have been possible without the 
support of Dr. Zbigniew Cichacz and the Peptide Array Core team.  
I would like to give special thanks to my friends Andy Ge, Jie Wang, 
Xiaofang Bian and Xiaobo Yu. They provided me with tremendous emotional 
support and have encouraged me all along the way.  
 vi 
TABLE OF CONTENTS 
                                                                                                              Page 
LIST OF TABLES ............................................................................................ xii 
LIST OF FIGURES .......................................................................................... xiii 
CHAPTER 
     1 INTRODUCTION ....................................................................................... 1 
          1.1 Breast Cancer ....................................................................................... 1 
               1.1.1 Overview of Cancer ...................................................................... 1 
               1.1.2 Overview of Breast Cancer ........................................................... 2 
               1.1.3 Overview of Transgenic Mouse Model ......................................... 4 
          1.2 Current Breast Cancer Diagnosis and Biomarkers ................................ 6 
               1.2.1 Statistics Preparation for Diagnosis and Biomarker ....................... 6 
               1.2.2 Current Clinical Diagnostic Methods of Breast Cancer ................. 7 
                    1.2.2.1 Breast Self-Examination (BSE) ............................................. 7 
                    1.2.2.2 Clinical Breast Examination (CBE)....................................... 8 
                    1.2.2.3 Mammography ..................................................................... 8 
                    1.2.2.4 Adjunctive Testing: Ultrasound Imaging and MRI .............. 10 
                    1.2.2.5 Molecular Diagnosis Platform ............................................. 11 
               1.2.3 Benefit of Early Detection and Treatment ................................... 12 
                         1.2.3.1 Early Diagnosis of Breast Cancer Improve Survival Rate13 
 vii 
CHAPTER                                                                                                          Page 
                         1.2.3.2 Proposed Early Diagnosis and Treatment Scenario ......... 14 
          1.3 Early Detection of Breast Cancer by Antibodies ................................. 15 
               1.3.1 Overview of Blood Based Breast Cancer Biomarkers ................. 15 
               1.3.2 Challenges in Finding Early Breast Cancer Biomarker................ 17 
               1.3.3 Cancer Antibodies as Biomarkers ............................................... 19 
                    1.3.3.1 Patients can Develop Autoantibodies Against Tumor Early . 19 
                    1.3.3.2 Advantage of Using Antibodies as Biomarker ..................... 21 
                    1.3.3.3 Breast Cancer Associated Antibodies .................................. 24 
               1.3.4 Emerging Technologies for Profiling Antibody Responses ......... 25 
                    1.3.4.1 SEREX ............................................................................... 25 
                    1.3.4.2 Peptide and Peptoid Microarrays ......................................... 27 
                    1.3.4.3 SERPA ............................................................................... 28 
                    1.3.4.4 Protein microarray .............................................................. 29 
          1.4 Immunosignature ............................................................................... 31 
               1.4.1 Definition of Immunosignature ................................................... 31 
                    1.4.1.1 Building a Complex Chemical Surface................................ 32 
                    1.4.1.2 Probing Sera ....................................................................... 33 
                    1.4.1.3 Analysis of Binding Pattern ................................................ 33 
               1.4.2 Advantage of Immunosignature .................................................. 34 
 viii 
CHAPTER                                                                                                          Page 
               1.4.3 Published Studies with Immunosignature.................................... 36 
          1.5 Breast Cancer Treatment .................................................................... 36 
               1.5.1 Clinical Treatment of Breast Cancer ........................................... 36 
                    1.5.1.1 Surgery and Radiotherapy ................................................... 37 
                    1.5.1.2 Cancer Drugs ...................................................................... 39 
                         1.5.1.2.1 Chemotherapy ............................................................. 39 
                         1.5.1.2.2 Hormone Therapy ....................................................... 40 
                         1.5.1.2.3 Targeted Therapy ........................................................ 40 
               1.5.2 Emerging Strategy of Immune Checkpoint Blockade .................. 41 
     2 Early Detection Of Breast Cancer .............................................................. 45 
          2.1 Introduction........................................................................................ 45 
          2.2 Results ............................................................................................... 48 
               2.2.1 HER2 Transgenic Mouse Model ................................................. 48 
               2.2.2 Scheme of Experiment Design .................................................... 50 
               2.2.3 Influence of Genetic Background on Immunosignature ............... 51 
               2.2.4 Pre-tumor Immunosignature Prior to Tumor Palpation ................ 52 
               2.2.5 Earliest Time Point of the Detectable Immunosignature .............. 53 
               2.2.6 Time Course of Immunosignatures During Tumor Progression  .. 54 
               2.2.7 Cross-stage Prediction ................................................................ 59 
 ix 
CHAPTER                                                                                                          Page 
          2.3 Methods ............................................................................................. 60 
               2.3.1 Mice and Sample Collection ....................................................... 60 
               2.3.2 Preparation of Microarray ........................................................... 61 
               2.3.3 Probing Serum Antibodies on Peptide Microarrays ..................... 62 
               2.3.4 Microarray Data Processing ........................................................ 62 
               2.3.5 Statistical Analysis ..................................................................... 63 
          2.4 Discussion .......................................................................................... 63 
          2.5 Supplements ....................................................................................... 68 
               2.5.1 Selection of multiple batches of array ......................................... 68 
               2.5.2 Removal of Batch Effect............................................................. 69 
     3 A MODEL FOR THE EARLY DETECTION AND TREATMENT OF 
CANCER .......................................................................................................... 74 
          3.1 Abstract.............................................................................................. 74 
          3.2 Introduction........................................................................................ 75 
          3.3 Results: .............................................................................................. 77 
               3.3.1 Early Detection of Breast Cancer and PD-L1 Treatment ............. 77 
               3.3.2 Inhibition of Tumor Growth Rate by Early Treatment ................ 79 
               3.3.3 RNA Expression of PD-L1 in Mammary Glands ........................ 80 
               3.3.4 Changes of Immunosignatures After PD-L1 Treatment ............... 82 
 x 
CHAPTER                                                                                                          Page 
          3.4 Methods ............................................................................................. 84 
               3.4.1 Mice and Sample Collection ....................................................... 84 
               3.4.2 Binding of Sera to the Peptide Microarrays ................................. 84 
               3.4.3 PD-L1 Treatment Regime ........................................................... 85 
               3.4.4 RNA Expression in Mammary Gland ......................................... 86 
               3.4.5 Statistical Analysis ..................................................................... 87 
          3.5 Discussion .......................................................................................... 87 
REFERENCES .................................................................................................. 93 
APPENDIX 
     A DETECTION OF OSTEOSARCOMA RECURRENCE IN CLINICAL 
CANINE SAMPLES BY IMMUNOSIGNATURE .......................................... 118 
          AP1.1 Introduction ................................................................................. 119 
               AP1.1.1 Background of Osteosarcoma .............................................. 119 
               AP1.1.2 Current Diagnosis and Treatment of OSA: ........................... 120 
               AP1.1.3 Recurrence of OSA .............................................................. 120 
          AP1.2 Result and Discussion ................................................................. 121 
               AP1.2.1 Canine Osteosarcoma Clinical Sample Summary ................. 121 
               AP1.2.2 Correlation Analysis Of Overall Antibody During OSA....... 122 
               AP1.2.3 Comparison of Immunosignature at Multiple Time Points ... 124 
 xi 
CHAPTER                                                                                                          Page 
               AP1.2.4 Conclusion and Future Direction ......................................... 127 
          AP1.3 Methods ...................................................................................... 128 
               AP1.3.1 Sample Summary ................................................................ 128 
               AP1.3.2 Binding of Sera to the Peptide Microarrays .......................... 129 
               AP1.3.3 Statistical Analysis .............................................................. 129 
     B CHARACTERIZATION OF ANTIBODY PROFILE DURING CANCER 
DEVELOPMENT............................................................................................ 131 
          AP 2.1 Quantitative Characterization Of Antibody Profiles During Tumor 
Development ................................................................................................... 132 
               AP2.1.1 Introduction ......................................................................... 132 
               AP2.1.2: Result and Discussion ......................................................... 133 
          AP2.2 A Time Series Study of Antibody Profile Along Tumor 
Development ................................................................................................... 138 
               AP2.2.1 Introduction ......................................................................... 138 
               AP2.2.2 Result and Discussion .......................................................... 139 
          AP2.3 Robustness of immunosignature .................................................. 146 
               AP2.3.1 Introduction ......................................................................... 146 
               AP2.3.2 Result and discussion:.......................................................... 147 
     C PERMISSIONS ....................................................................................... 150 
BIO SKETCH ................................................................................................. 152 
 xii 
LIST OF TABLES 
Table                                                                                                                   Page 
2.1: Cross-Stage Prediction Performance in the Training Set ............................. 60 
2.2: Correlation Analysis for Different Printing Batches of Slides ...................... 68 
2.3: Statistic Characterization of Different Batches of Slides ............................. 69 
3.1: The Timeframe for Occurrence of Signatures, Palpable Tumor and 
Treatments ......................................................................................................... 78 
AP1.1: Canine Osteosarcoma Clinical Sample Summary ................................. 121 
AP1.2: Correlation Analysis of Overall Antibody Profile ................................. 123 
AP1.3: Distribution of Fold Change in Selected Peptides ................................. 123 
AP1.4: Proportion of Overlapped Peptides ....................................................... 126 
AP2.1: Statistic characterization of All Time Points for Each Mouse ............... 136 
AP2.2: Sample Information for Tg8-1-1 and WT2-3 ........................................ 140 
AP2.3: Sample Information for Tg8-3-9 and WT1-3 ........................................ 141 
AP2.4: Sample Information for Robustness Test .............................................. 147 
 
  
 xiii 
LIST OF FIGURES 
Figure                                                                                                                 Page 
1.1 Biology of Breast Tissue ................................................................................ 2 
1.2: Illustration of Mammogram and MRI ........................................................... 7 
1.3: Five-Year Relative Survival Rates (%) by Stage in US ............................... 13 
1.4: Distribution of Human Plasma Protein. ....................................................... 22 
1.5: Principle of Immunosignature ..................................................................... 32 
1.6: Introduction of CTLA-4 and PD-1 Treatment ............................................. 43 
1.7: Biology and Mechanism of Anti-PD-L1 Antibody Treatment ..................... 44 
2.1: Tumor Free and Growth Curve of FVB/N NeuN Mouse Model .................. 49 
2.2: Scheme of Experiment Design .................................................................... 50 
2.3: Influence of Genetic Background on Immunosignature ............................... 52 
2.4: Immunosignature Can Show a Separation Between Transgenic Mice and Age 
Matched Controls Two Weeks Before First Palpable Tumor .............................. 53 
2.5: Heatmap of Immunosignatures of Different Time Points in Tumor 
Development…. ................................................................................................ 54 
2.6: Time Course of Immunosignatures During Tumor Progression in FVB/N 
NeuN Mice ........................................................................................................ 56 
2.7: Venn Diagram of Different Immunosignatures Along Tumor Development 58 
2.8: Numbers of Selected Peptides Overlap Between Two Adjacent Stages During 
Tumor Development .......................................................................................... 58 
 xiv 
Figure                                                                                                                 Page 
2.9: Numbers of Selected Peptides Overlap Between Earliest Tumor Signature 
with Other Stages Signatures ............................................................................. 59 
2.10: Principle Component Analysis of Different Batches .................................. 70 
2.11: Correlation of Technical Replicates Before and After SVA Adjusted and 
PCA Analysis of Batch Effects .......................................................................... 71 
2.12: Correlation of Technical Replicates Before and After Combat Adjusted and 
PCA Analysis of Batch Effects .......................................................................... 72 
2.13: Comparison of Different Batch Effect Removal Methods.......................... 73 
3.1: Cartoon of Experimental Design Outline..................................................... 78 
3.2: Tumor Growth Characteristics in FVB/N NeuN α-PD-L1 Treatment 
Experiment ........................................................................................................ 80 
3.3: RT-PCR Analysis of MMTV Promotor and PDL1 Expression in Established 
Tumors and Adjacent Normal Mammary Glands ............................................... 81 
3.4: Heatmap Showing PD-L1 Generated Immunosignature .............................. 83 
AP1.1: Proportion of Overlapped Peptides Shared Among Different Time    
Points .............................................................................................................. 125 
AP1.2: Intensity Plot of Significant Peptides Between Primary and Recurrent 
OSA ................................................................................................................ 126 
AP2.1: Summary of Mice Samples .................................................................. 134 
AP2.2: Tumor Growth Curve for Tg8_1-1 and Tg8_3-9 Mice ......................... 134 
AP2.3: AbStat Time Course for Tg8-1-1 and WT2-3 Mice .............................. 135 
 xv 
Figure                                                                                                                 Page 
AP2.4: AbStat Time Course for Tg8-3-9 and WT1-3 Mice .............................. 136 
AP2.5: Entropy Time Course for Transgenic and Wild Type Mice .................. 137 
AP2.6: Concept of Autocorrelation Function and Durbin-Watson Test ............ 142 
AP2.7: Self-Organizing Map to Cluster 249 Autocorrelated Peptides in            
Tg8-3-6. .......................................................................................................... 143 
AP2.8: Self-Organizing Map to Cluster 849 Autocorrelated Peptides in            
Tg8-3-6. .......................................................................................................... 144 
AP2.9: Intensity of a Cluster of 24 Autocorrelated Peptides Correlated with 
Tumor Development ........................................................................................ 145 
AP2.10: Concept of Robustness in Immunosignature ....................................... 147 
AP2.11: Correlation of Selected Peptides in Transgenic (Tg) and Wild-Type (WT) 
Control Mice. .................................................................................................. 148 
AP2.12: Correlation of All Peptides on the 10K Array ..................................... 149 
 
 1 
CHAPTER 1  
INTRODUCTION 
1.1 Breast Cancer 
1.1.1 Overview of Cancer 
Cancer is a group of diseases characterized by the uncontrolled growth 
and spread of abnormal cells [1]. Hanahan and Weinberg propose the following 
hallmarks of cancer: self-sufficiency in growth signals; evasion of growth 
suppressors; limitless replicative ability; resistance to apoptosis; sustained 
angiogenesis; activation of invasion and metastasis; evasion of immune 
destruction; and deregulation of energy metabolism [2, 3]. Genome instability and 
mutation and tumor-promoting inflammation are enabling characteristics of 
cancer cells [3]. Cancer is the leading cause of morbidity and mortality in the 
world. In 2012, there were approximately 14 million new cancer cases, and cancer 
accounted for 8.23 million deaths [4]. Worldwide in 2012, the five most common 
cancers in women were breast, colorectal, lung, cervical, and stomach. For men, 
they were lung, prostate, colorectal, stomach and liver cancer.  In the year of 2015, 
cancer accounted for 589,430 deaths in US, and 78% of those diagnosed cancer 
are in people 55 years or older. In the next two decades, the number of new cancer 
cases worldwide is expected to increase by more than 70% [4]. Many factors can 
increase cancer risk, such as genetic background, viral infections, obesity, low 
fruit and vegetable intake, use of tobacco and alcohol and others [1, 4].  
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1.1.2 Overview of Breast Cancer 
Most of following information is from the SEER Cancer Statistics Review 
and the American Cancer Society [5, 6].  
Breast cancer is a type of malignant tumor initiated in breast. A normal 
breast is made of lobules to secret breast milk, ducts that carry milk from lobules 
to the nipple, connective tissue, blood vessels and lymph nodes (Figure 1.1).  The 
lymph system of the breast is the primary way that tumor cells spread outside the 
breast. It includes lymph nodes and vessels that carry lymph. When breast cancer 
cells spread into the lymph system, cancer cells will reside in the local lymph 
nodes or later spread to other organs through metastasis.  
Figure 1. 1 Biology of Breast Tissue 
Figure adapted from American Cancer Society with permission [6].  
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There are several major types of breast cancer. When abnormal cells 
originate in the ducts, the cancers are ductal. According to whether or not 
abnormal cells invade the walls of ducts and spread to nearby lymph nodes and 
other breast tissues, ductal carcinoma is either ductal carcinoma in situ (DCIS) or 
invasive ductal carcinoma (IDC).  IDC is the most common type of breast cancer. 
Different from DCIS and IDC, invasive lobular carcinoma (ILC) start in the cells 
lining the lobules and become invasive. Inflammatory breast cancer (IBC) is a 
rare type of invasive breast cancer. Patients with IBC typically have breast skin 
that is red, thick and pitted in texture. IBC patients may also feel their breast 
become bigger, hard or itchy. IBC does not present with abnormal lump and is 
likely to be missed by a mammogram.  
Cancer stages describe the extent of a cancer in a patient. In general, 
cancer stages can be divided into localized when cancer cells are only found in 
breast; regional when cancer cells spread into regional lymph nodes; or metastatic 
when the cancer cells spread to distant organs.  
Breast cancer is the most common cancer and the second leading cause of 
death among women in the United States. In 2012, nearly three million women 
were living with breast cancer in the US. It is estimated that, in 2015, there will be 
231,840 new cases of invasive breast cancer (14% of all new cancer cases) and 
40,290 breast cancer deaths (6.8% of all cancer deaths) in the United States. 12.3% 
of women (one in eight) will be diagnosed with breast cancer during their lifetime. 
The five-year relative survival rate is used to calculate the proportion of patients 
expected to be alive five years after diagnosis compared with a general population 
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of the same age, race and sex that haven’t been diagnosed with cancer.  Based on 
data from the Surveillance, Epidemiology and End Results Program (SEER) 
2005- 2011, breast cancer has a five-year relative survival rate of 89.4%. If we 
consider different stages of breast cancer, localized breast cancer account for 61% 
of new breast cancer cases, while regional and distant account for 32% and 6% of 
new cases, respectively.  
According to American Cancer Society data, in the year of 2015, 61% of 
breast cancer cases are detected at a localized stage, with a five-year relative 
survival rate of 99% [1]. However, when tumors spread to nearby lymph nodes or 
other tissues, the survival rate decreases to 85% [1]. If the breast cancer is in a 
more advanced stage, where tumors are found in lymph nodes around the 
collarbone or in distant organs, the survival rate falls to 25% [1].  Cancer can 
reoccur well after the 5 year time period. Women who have had breast cancer live 
in the fear of recurrence all the time.  
1.1.3 Overview of Transgenic Mouse Model 
The mouse has played an important role in studying the basic biology of 
breast cancer. With more understanding of the molecular basis of breast cancer 
development, different oncogenes are engineered into mice to manifest 
overexpression of a specific oncogene or depletion of a specific tumor suppressor 
gene in mouse germ line cells. Over 100 different genetically engineered—also 
called transgenic—mouse models have been constructed and studied, including, 
HER2, p53, c-myc, TGFa, Cyclin D1 and many others [7-10].  The use of 
transgenic mouse models allows researchers to study breast cancer samples that 
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are difficult to access in clinical trials such as the Women's Health Initiative (WHI) 
study and the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer-screening 
trial. Multiple time points of samples that cover different stages of tumor 
development can be collected in a well-controlled manner. This creates a huge 
advantage in the study of early-stage breast cancer, as human early-stage cancer 
samples are scarce. 
In order to correctly represent breast cancer development in humans, the 
mouse models must have enough similarity with human breast cancer 
development—in both genetic and protein-based comparisons—so that the 
discoveries in mice may be applied to human breast cancer diagnostics.  
Herschkowitz and colleagues have shown that transgenic breast cancer mouse 
models have significant genetic similarities to human breast cancer. They used six 
models with different transgenes to represent different human subtypes of breast 
cancer. Many of the defining characteristics of human breast cancer can be seen in 
the mouse models [9]. In the area of immune response, Lu and colleagues used a 
transgenic mouse model with overexpression of the neu oncogene that developed 
a serum autoantibody repertoire similar to that in cancer patients [11]. 
In this study, I use the MMTV-neuN mouse model, which is the most 
extensively studied breast cancer model in prevention studies [8]. The neuN gene 
is the mouse homolog of the human Erbb2 gene, which is overexpressed in about 
20% - 30% of human breast cancers [12]. The neuN gene is overexpressed in 
mouse mammary glands under the transcriptional control of the mouse mammary 
tumor virus promoter long terminal repeat (MMTV-LTR) [13]. This mouse model 
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has been used to test different cancer vaccines to prevent tumor development [14-
18]; to find biomarkers for breast cancer [9, 11, 19]; to test different drug 
treatments [20-23]; and to study basic mechanisms of breast cancer [9, 13, 24-27].  
The MMTV-neuN mouse model shares a great similarity with human 
breast cancer. However, it also has its limits. The cellular morphology is different 
from that of human breast cancer. This mouse model can represent human ductal 
carcinoma in situ (DCIS) but not lobular intraepithelial neoplasia. At late stages 
of tumor development, bone and brain metastases are missing from this model 
[12]. Overall, transgenic mouse models serve as a relevant, rapid and inexpensive 
system to investigate breast cancer in humans [8, 10]. 
1.2 Current Breast Cancer Diagnosis and Biomarkers 
1.2.1 Statistics Preparation for Diagnosis and Biomarker 
In order to measure the performance of a diagnostic test or a biomarker, 
sensitivity, specificity and accuracy are often used. In a diagnostic test of a 
disease, a positive call means that the test score of a sample is positive for the 
disease. A negative call means that the sample’s test score is negative for the 
disease. In a test with an overall population of (A+B+C+D), A is the number of 
positive samples that actually have the disease. B means non-diseased samples 
that score positive. C means diseased samples that score negative. D is the 
number of negative samples that do not have the disease.  
Sensitivity is the measure of the proportion of positive samples in overall 
samples actually with the disease -A/(A+C). Specificity describes the proportion 
of negative samples among the samples without the disease –D(B+D). The false 
 7 
positive rate, which equals 1-specificity, is more frequently used. Accuracy is the 
proportion of positive and negative samples that are correctly predicted to the 
actually disease condition in the overall population- (A+D)/(A+B+C+D). 
1.2.2 Current Clinical Diagnostic Methods of Breast Cancer 
The American Cancer Society provides screening guidelines for “early 
detection of cancer in average-risk asymptomatic people” for 2015[1]. Breast self-
examination (BSE), clinical breast examination (CBE) and mammography are 
recommended for women over age 20 (Figure 1.2). Ultrasound (US) and magnetic 
resonance imaging (MRI) are also additional diagnostic tests widely used in 
clinical settings [28].  
Figure 1. 2: Illustration of Mammogram and MRI 
Figure adapted from American Cancer Society with permission [6].  
 
1.2.2.1 Breast Self-examination (BSE) 
Adult women at the age of 20 should begin to do BSE at least once a 
month and report any new breast symptoms to healthcare professionals. 
Symptoms include changes in how the breast feels, its appearance, and any 
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discharge from nipple. Specific symptoms include lumps, nipple tenderness, 
thickening of the breast, skin texture changes and others. BSE can be done 
routinely and allows patients to monitor their breasts regularly. Although BSE 
serves as a good tool to self-monitor for any abnormal breast symptoms, when 
such symptom occurs, a clinical breast examination should be performed [1, 29]. 
1.2.2.2 Clinical Breast Examination (CBE) 
A clinical breast examination is a clinical exam performed by a healthcare 
professional that is trained to diagnosis abnormal breast symptoms. The goal of 
CBE is to check any lumps or physical changes in order to achieve early diagnosis 
of breast cancer. During the exam, a healthcare professional will check the 
patient’s breast to discover any unusual texture, lumps, and suspicious areas. If a 
lump is hard and cannot move easily, further tests are needed.  
For women in their 20s and 30s, CBE is recommended to be a part of 
patient’s periodic health examination at least once every 3 years. For 
asymptomatic women over 40, CBE is recommended annually.  When 
mammography and other sophisticated tests are not available, CBE is an easy way 
to perform breast cancer screening [1, 29].  
1.2.2.3 Mammography 
A mammogram is an x-ray image of the breast used to screen for breast 
cancer. During a mammogram, a patient’s breasts are compressed between two 
firm surfaces to spread out the breast tissue. The breasts then are exposed to small 
dose of iodizing radiation to produce an image of the breast tissue. A trained 
healthcare professional will examine the image to look for any sign of cancer. 
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Mammography is recommended annually for women over 40. Women with a high 
risk of breast cancer should consult with professionals on the advisability of 
mammography before age 40. The advantage of mammography is that it can often 
detect a breast lump before the patient can feel the lump. If the mammogram 
reveals an abnormal area in the breast, additional tests, such as ultrasound or MRI, 
should be offered, and a biopsy should be performed when test results show that 
the mass is solid[1, 29]. A mammogram is much more expensive than CBE, and, 
thus, it not feasible as a routine test for all women.  
The estimated sensitivity of mammography ranges from 29-97% with a 
mean of 77%, and the false-positive rate ranges from 1-29% with a mean of 10% 
[30]. Several clinical trials showed that mammography screening produced a 
projected 15-20% reduction in breast-cancer-related mortality [29]. Although 
mammography has played an important role in breast cancer diagnosis and has 
helped save lives, it has many critics. Mammography has limited sensitivity and a 
high false-positive rate [31, 32]. It has been shown to detect only 70% of breast 
cancers [33]. 54% of all patients that were diagnosed to have breast cancer by 
screening mammograms, up to 54% are results of overdiagnosis [34]. In addition, 
mammography tends to have low sensitivity in women with dense breast tissue 
[35, 36]. Women with aggressive breast cancer, such as triple negative breast 
cancer [37], and those younger than 50 years old [38] also benefit less [39].  
Around 80% of the false positives in mammography are caused by benign 
growths [40, 41].  Benign growths can be classified as proliferative, hyperplasia 
and hyperplasia/atypical growths [42, 43].  All three classes are associated with 
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different breast cancer risks compared to the risk for normal women. 
Hyperplasia/atypical growths account for a 4.5-fold increase in the risk for breast 
cancer [44]. However, mammography does not perform well to differentiate the 
three classes. Absolute mortality benefit for women screened annually for 10 
years is around 1% on average [45]. 
 Another concern about mammography is that the value of mammograms 
is associated with the experience of physician who interprets them [30]. 
Physicians who interpret 2500-4000 mammograms annually with a high screening 
focus have a 50% lower false-positive rate than physicians who interpret 480-750 
mammograms annually with a low screening focus[30].  This association between 
the physician’s experience and the performance of mammography may bias breast 
cancer diagnosis.  
1.2.2.4 Adjunctive Testing: Ultrasound Imaging and Magnetic Resonance 
Imaging (MRI) 
Ultrasound imaging uses high-frequency sound waves to view the breast 
tissue and can capture images in real time. During an ultrasound exam, a 
transducer is placed on the skin with a thin layer of gel in between to transmit 
ultrasound waves from the transducer into the patient’s body. MRI uses magnets 
and radio waves to produce images of the breast. MRI is the most sensitive 
imaging method for breast cancer detection [46]. 
Ultrasound and MRI are adjunctive diagnostic tests used when abnormal 
areas have been found in the breast. Although current evidence on adjunctive 
testing is limited, it has proved beneficial in identifying breast cancer in patients 
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who have dense breasts, as indicated by mammograms [29]. Most of the cancers 
detected by adjunctive tests are invasive ductal cancer (IDC) rather than ductal 
carcinoma in situ (DCIS) [47]. However, due to the high cost of MRI, it typically 
is used as adjunctive testing when something suspicious has been found, and not 
for screening of the general population. Also, it is important to note that 
adjunctive tests can increase the false-positive rate [29]. 
1.2.2.5 Molecular Diagnosis Platform 
Polymerase chain reaction (PCR) and DNA microarray are often used to 
detect specific mRNA or DNA sequences of breast cancer. The advantage of PCR 
is that it can perform low-noise amplification even when the signal is low-level.  
DNA microarray technology can simultaneously detect multiple sequences. The 
FDA has approved Oncotype DX, HOXB13-IL17BR assays and the MammaPrint 
assay to measure gene expression of breast cancer [48].  
Oncotype DX detects a 21-gene profile by reverse-transcriptase PCR to 
predict the risk of recurrence in patients taking Tamoxifen. Sixteen of the 21 
genes are cancer-related genes with reference genes. A mathematical algorithm is 
derived from empirical retrospective study to calculate a score to estimate the risk 
of distant recurrence [49].  
MammaPrint is a gene expression assay by Agendia that detects a 70-gene 
profile by reverse-transcriptase PCR. It used 117 patients with axillary lymph 
node-negative primary breast cancer to find genes highly correlated with a short 
interval from primary tumor to distant metastases. MammaPrint profiling is used 
to identify a sub-population of patients by their prognosis performance [50].  
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HOXB13-IL17BR assays use complementary DNA microarray 
technology to detect the expression level of HOXB13/IL17BR genes. It is used to 
predict the outcome of Tamoxifen in untreated ER-positive/node-negative patients 
[51].  
Current breast cancer diagnostic methods suffer from low sensitivity and 
high false-positive rates. Breast tumors with high breast density and aggressive 
growth are not detected during current diagnostic procedures [52, 53]. Moreover, 
CBE, mammography and adjunctive tests are not effective in the early detection 
of breast cancer. 
1.2.3 Benefit of Early Detection and Treatment 
Early detection of cancer identifies tumors before they are diagnosed can 
bring more opportunities for medical intervention. With early detection, it seems 
reasonable to expect that systematic therapy involving smaller amounts of less-
toxic medications can be initiated earlier for a shorter period of time and be more 
effective. This could potentially revolutionize current treatment strategies and 
improve patients’ outcomes—and, perhaps, even eradicate the disease.  Take 
ovarian cancer for example. Patients with stage I ovarian cancer, a 42-mm tumor 
diameter, on average, have a five-year survival rate of 92%. The five-year 
survival rate decreases to around 30% when patients are in stage III to stage IV 
[54]. Thus, researchers and medical professionals have spent considerable effort 
in seeking a noninvasive, simple and inexpensive means for the early detection of 
cancer. 
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1.2.3.1 Early Diagnosis of Breast Cancer Can Improve Survival Rate 
In cancer treatment, patients with localized cancer have better survival 
rates than those with metastatic disease (Figure 1.3) [55]. Failure to detect local 
cancer at an early stage is the major problem in cancer diagnosis and treatment.  
In breast cancer, in the localized stage, tumors have not spread to lymph 
nodes, nearby structures outside of the breast. According to American Cancer 
Society projected data for 2015, 61% of breast cancer cases are detected at a 
localized stage with a five-year relative survival rate of 99% [1]. However, when 
tumors spread to nearby lymph nodes or other tissues, the survival rate decreases 
to 85% [1]. If the breast cancer is in a late stage, in which tumors are found in 
lymph nodes around the collarbone or more distant, the survival rate falls to 25% 
[1].  Therefore, an early detection system could eliminate the mortality caused by 
late-stage metastasis and largely improve the five-year survival rate for patients. 
We currently lack a screening strategy to make a noninvasive, timely diagnosis. 
Figure 1. 3: Five-year Relative Survival Rates (%) by Stage at Diagnosis in 
US from 2004-2010 
Figure adapted from American Cancer Society with permission [1].  
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1.2.3.2 Proposed Early Diagnosis and Treatment Scenario 
In order to be successful, an early diagnosis system should have the 
following merits. First, it should have high sensitivity and a low false-positive rate 
for patients in the early stage of breast cancer. One of the main challenges with 
mammography is its high false-positive rate. The proposed early detection system 
is a screening system for the general population or the sub-population of patients 
that have found an abnormality during self-exam. Second, the cost of diagnosis by 
this system should be low so patients can be examined routinely. Although MRI 
has the highest sensitivity to detect small tumors, its high cost prevents patients 
from having MRIs frequently. The cost of an early detection system should be 
less than the cost of clinical breast examination. Another advantage of routine 
examinations is that they can increase prediction accuracy [56]. For example, a 
test with 95% accuracy per test will be have 99.75% accuracy after two tests and 
99.99% after three tests. Routine testing allows establishing a baseline which 
should also decrease false positives. In order to allow for routine examinations, 
the system needs to use non-invasive techniques to screen asymptomatic 
populations. Blood, saliva or other fluids could be good candidates to be used in 
the test.  
I propose a scenario for early detection of breast cancer through routine 
examinations. Patients will perform breast self-examination to find any lump and 
use an early detection system to monitor any aberration. If the system was simple 
and inexpensive, patients could get the diagnosis result well before lump was 
detected. Further testing by mammography, MRI, ultrasound and others will be 
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performed when the test shows an increased risk of breast cancer. Early surgery 
and therapy will be used to kill the cancer using a low-dose, non-toxic treatment.  
Some people may argue that the early diagnosis of breast cancer will 
increase the financial burden on patients and society. Their logic assumes that if a 
test has 99% specificity, and over 100 million US women are over age 20[57], 
annual detection will lead to one million false-positive cases. If the cost of a 
follow-up mammogram for every false positive is around $100, this will lead to 
100 million dollars in unnecessary costs per year. However, this description 
totally ignores the increased sensitivity of the early diagnosis system. Also, new 
therapies may appear with the early detection system. The regimen of drugs 
targeting early-stage cancer could be different from the current ones targeting 
later-stage cancer. Because the target for early diagnosis is the general population, 
the market for drugs to treat early breast cancers will increase dramatically and, 
thus, reduce the costs of drug development and manufacture. This has already 
been seen in many drugs; a prime example is aspirin, first marketed by Bayer in 
1932 and, today, a very low-cost widely-used drug. 
1.3 Early Detection of Breast Cancer by Antibodies 
1.3.1 Overview of Blood Based Breast Cancer Biomarkers 
Current molecular approaches for detecting breast cancer can fall into two 
categories: 1. direct detection of the tumor or molecular tumor cells shed; 2. 
detection of the patient’s immune response to the tumor.  
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Biomarkers that detect the tumor or the cells it sheds include proteins, 
miRNAs, circulating tumor cells (CTC), aberrant glycosylation and others. 
Biomarkers that detect the immune response of patients include antibodies that 
will be discussed in the following section.  
CA 15-3 and CA27.29 are biomarkers to detect the circulating MUC-1 
antigen in the blood. They are different epitopes on the same MUC-1 antigen. A 
high CA 15.3 level is correlated with a large tumor size and presence of lymph 
node metastases [58]. These biomarkers have been shown to have prognostic 
value in early-stage breast cancer [58]. According to the American Society of 
Clinical Oncology guidelines, CA 15-3 and CA27.29 are not recommend for 
screening, diagnosis and staging of primary and recurrent breast cancer because 
their role in early-stage breast cancer and treatment decisions is not clear [59].  
HER2 is a member of the epidermal growth factor receptor (EGFR) family 
70. 15% -30% of diagnosed breast cancers have an overexpression of HER2 [60]. 
It is recommended that HER2 expression be evaluated in primary invasive breast 
cancer from the time of diagnosis to recurrence [60],[61]. It can help to guide the 
use of trastuzumab in the adjuvant setting [62].  
Circulating tumor cells (CTC) are tumor cells present in the blood that 
represent a specific cancer type. CTC may predict the presence of micrometastasis 
or aggressive primary breast cancer [63]. However, the low concentration of 
CTCs (1 in 106~107 leukocytes) [63, 64] makes it difficult to be captured by 
immunomagentic beads or to use RT-PCR to amplify signals [65-67]. The CTC 
assay is not recommended in the guidelines for diagnosing breast cancer.  
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Changes in circulating microRNAs (miRNAs) have been found to be 
significantly related to early and minimally invasive breast cancer. A panel of 31 
candidate miRNAs has shown significant differences between 20 women with 
early-stage breast cancer and 20 control patients [68]. Another study, using a 
panel of seven  miRNA candidates in 148 patients with breast cancer and 44 
controls, showed significantly altered miRNA expression levels [69]. Tumor-
specific miRNAs are tissue-specific, dysregulated in cancer, highly abundant and 
stable in the blood [70, 71]. miRNAs could serve as a good candidate for non-
invasive biomarkers.  
Aberrant glycans and glycoforms of proteins could also be a source of 
breast cancer biomarkers to monitor disease progression. Abd Hamid and 
colleagues discovered that a trisialylated triantennary glycan containing alpha1, 3-
linked fucose with a twofold increase in breast cancer patients compared with 
controls [72].  
Although early diagnosis of breast cancer has many merits, only limited 
biomarkers have been discovered and widely used in the clinical setting. Methods 
to identify novel breast cancer biomarkers are still urgently needed. Each 
approach has its strengths and weaknesses. No single technology can provide the 
ideal detection performance with high sensitivity and specificity. 
1.3.2 Challenges in Finding Early Breast Cancer Biomarker 
In order to be useful in early detection of breast cancer, a biomarker 
should have high sensitivity and a low false-positive rate, and it should show 
evidence of value in determining treatment after the early detection. The 
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biomarker should also be stable and robust and available in a non-invasive test. 
However, with thousands of candidate biomarkers identified, only a few are 
approved each year and widely used in the clinic [29, 59].  Clearly, searches for 
biomarkers for early detection have not yet been generally successful [73-75]. 
Researchers in early detection of breast cancer face several challenges, including 
over-fitting of the algorithm by small sample size, unstandardized sample 
preparation and specimen annotation [76, 77].   
In early detection studies, one problem is that most biomarkers are 
discovered from diagnosed cancers and then are used in an attempt to diagnose 
early cancer. From the biology of cancer, tumors change dynamically at different 
stages. Samples at the time of diagnosis are most likely to be irrelevant for early-
stage samples. Antigens in early high-risk lesions may have a different expression 
panel from later stages.  
The reason that many researchers still use samples with diagnosed tumors 
is that samples from the same patients before and after tumor diagnosis are hard to 
get. It is difficult to study the correlation of a biomarker with tumor progression 
and early-stage breast cancer without the proper early-stage samples. 
Many clinical studies also have suggested that using biomarkers 
discovered and widely used in diagnosing cancer perform poorly in pre-diagnostic 
patients [78-81]. Zhu and colleagues studied 118 patients one to two years before 
ovarian cancer diagnosis [79]. Among 28 evaluated biomarkers, CA125 achieved 
the highest score, with a sensitivity of 69.2% and a specificity of 96.6% in 
diagnosed samples but failed in pre-diagnostic samples. Other models had poorer 
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performance than CA125 alone. Zhu et al. concluded that “biomarker panels 
discovered in diagnostic samples may not validate in pre-diagnostic samples.”  In 
the Carotene and Retinol Efficacy Trial, Anderson and colleagues showed they 
could achieve only limited discriminatory power in pre-diagnostic ovarian 
specimens and that the power increased as the time of diagnosis approached [78]. 
In breast cancer, Lu and colleagues used a sample 150 days before diagnosis, and 
HER2 achieved a ROC score of only 0.63 and p53 with 0.63 [81]. In the Prospect-
EPIC study, Opstal-van Winden and colleagues used samples from 68 women 
with a median of 21.3 months before breast cancer diagnosis and 68 controls. 
After evaluation of ten breast cancer biomarkers, none of those resulted in correct 
classification [80]. In these studies, researchers concluded that markers 
discovered in diagnostic samples may not be validated in pre-diagnostic samples. 
1.3.3 Cancer Antibodies as Biomarkers 
1.3.3.1 Cancer Patients can Develop Autoantibodies Against Tumor Early 
The immune system in our bodies protects us from pathogens and 
abnormal conditions.  It continuously monitors any for foreign invader. B cells 
from the humoral immune system and T cells from the cellular immune system 
play important roles in finding non-self-antigens. Antibodies produced by B cells 
bind to specific antigens and neutralize the foreign invader. After binding, B cells 
are activated and form a memory response to encounter future events from the 
same antigen.  
T cells are also triggered and help B cells to carry out cytotoxic killing of 
infected cells. In order to correctly recognize foreign antigens instead of self-
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molecules, B cells and T cells are negatively selected to remove any B cells and T 
cells that can bind to self-proteins.  
Cancer cells start as normal cells and enter into atypical growth later. The 
abnormal changes lead to changes in the abundance of protein expression, 
different post-translational modification patterns, and other changes. Burnet and 
Thomas developed an immune surveillance hypothesis in 1971 after Ehrlich 
proposed that the immune system can recognize and destroy nascent transformed 
cells in the human body [82]. The formal immune surveillance describes that 
thymus-dependent immune cells can produce an effective immune response to 
tumor antigens and protect the host from nascent transformed cells [83-85]. Later, 
this theory was refined by an immune-editing concept that shows that there is a 
dynamic interaction between the immune system and the tumor. In the refined 
theory, immune surveillance inhibits tumor development from tumor initiation, 
and the tumor evolves through multiple mechanisms to avoid immune system 
surveillance [86, 87]. 
A classic example that reflects the role of antibodies early in cancer can be 
found in the paraneoplastic syndrome (PNS) [88]. PNS is a syndrome that results 
from a cancer causing an autoimmune effect on the nervous system. When a 
tumor and nervous tissue share common an antigen, then remote pathologic 
effects will influence the nervous system. Sometimes the symptoms of PNS are 
detected months to years before the formation of a malignant tumor because 
tumor cells express neuronal antigens and trigger an anti-tumor immune response 
[89]. This is further supported by Marcia Wilkinson and colleagues, who 
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discovered a neuronal antibody in the serum of patients with small-cell lung 
cancer [88, 90].  After removal of the cancers, PNS is usually cured. These 
findings reveal that tumors elicit an anti-tumor antibody response at early stages 
[88, 91].  
More research has shown that autoantibodies can be found several months 
to years before the appearance of symptoms of lung cancer [92], esophageal 
squamous cell carcinoma [92], prostate cancer [93], breast cancer [94], and others 
[91, 95, 96].  
B cells have been detected in invasive breast cancer [97], a phenomenon 
called immune infiltration. This shows that the immune system closely monitors 
cancer cells. In 2005, p53 antibodies were detected in 12 of 49 individuals who 
developed cancer later, compared with four out of 54 individuals who did not [98]. 
Autoantibodies against HER2 have also been detected in early-stage breast cancer 
patients [99]. Evidence of autoantibodies to tumor-associated antigens (TAAs) 
precedes manifestations of diagnosed breast cancer, making autoantibodies a 
source of biomarkers to detect breast cancer early.   
1.3.3.2 Advantage of Using Antibodies as Biomarker 
Although the discovery of biomarkers for early diagnosis of breast cancer 
holds great promise, the low concentrations of biomarkers in blood impede the 
development of effective tests. Current plasma protein biomarkers in the human 
proteome organization (HUPO) project are in the range of ug/ml to mg/ml (Figure 
1.4). When using proteins and miRNA secreted from tumors or circulating cells as 
biomarkers to detect early-stage cancer, they are 10-fold4 too low to be detected 
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by state-of-the-art technology [100-102]. At the time of diagnosis by current 
biomarker technology, presumably a tumor would be larger than 1mm3 in size, 
with more than three million cells, and would have been developing in body for 
several years. It is not feasible to detect such a low signal without any 
amplification technology to extract and amplify the tumor-specific signal. Tumor- 
specific antibodies are the perfect biomarker candidate to amplify tumor-specific 
signals [103].  
Figure 1. 4: Distribution of Human Plasma Protein.  
Figure adapted from Anderson et al. with permission [101].  
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After activation, a B cell can produce 300,000-1,200,000 antibodies per 
hour [104, 105] and replicates every 70 hours [106]. It has a lifespan of up to 4.5 
months [107, 108]. B cells towards a tumor antigen can amplify the production of 
tumor-specific antibodies up to ~10-fold11 in one week [109, 110]. Memory B 
cells that generated those antibodies can exist years after the immunogenic event 
occurs. 
Antibodies are also stable and resistant to common types of proteolysis. 
Other proteins and small molecules will be either rapidly degraded or cleared 
from the blood. Antibodies have a half-life of over seven days in the blood. Even 
after separation from the blood, antibodies are stable for several years [111, 112]. 
This means that we can store achieved blood samples in sera or a standard filter 
spot [113]. This allows researchers to use stored, historical samples to find 
antibody biomarkers [114].  
Antibodies are also easy to detect. Each subtype of human 
immunoglobulin shares the same Fc structure on heavy chains. Commercial 
antibodies specifically binding to each subtype of human immunoglobulin are 
widely available with high specificity and affinity. This means that researchers 
can use the same secondary antibody to detect different tumor-specific antibodies 
(primary antibody), thus largely reducing the complexity of developing a 
biomarker.   
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1.3.3.3 Breast Cancer Associated Antibodies 
Much effort has gone into finding antibody biomarkers to diagnosis breast 
cancer.  ELISA, protein array and other technologies have been used to study 
single biomarkers and a panel of multiple biomarkers.  
Early in 1997, Disis and colleagues found the presence of the HER2 
antibody in 12 of 107 breast cancer patients and none among the 200 normal 
controls. They showed that nine of 44 patients with HER2- positive tumors had 
antibodies against HER2 [115]. Autoantibodies against HER2 have been detected 
in early-stage breast cancer patients [99].  Later, in 2005, p53 antibodies were 
detected in 12 of 49 individuals who developed cancer later, compared with four 
out of 54 individuals without cancer [98]. This study, for the first time, showed 
the relationship between p53 autoantibodies and the subsequent development of 
malignancy. A panel of multiple antibody biomarkers was investigated to increase 
prediction performance. Chapman and colleagues reported a panel of six antigens 
(p53, c-myc, HER2, NY-ESO-1, BRCA2 and MUC1) to distinguish patients’ 
samples of primary breast cancer from normal and ductal carcinoma in situ. 
Antibody response was observed in at least one of six antigens in 64% of primary 
breast cancer samples and 45% of DCIS samples with 85% specificity [116]. 
Anderson and colleagues used a protein microarray to discover 28 tumor antigens 
that can distinguish invasive breast cancer (stages 1-3) from benign breast disease 
[95]. Desmetz and colleagues focused on autoantibody biomarkers in in-situ 
carcinoma (CIS) in younger women under age 50) with breast cancer. They used a 
panel of antibodies against PPIA, PRDX2, FKBP52, HSP60 and MUC1 to study 
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60 primary breast cancer patients, 82 CIS patients and 93 healthy controls. The 
panel of biomarkers significantly distinguished primary breast cancer with AUC 
of 0.73 and CIS with AUC of 0.80 from healthy controls [117]. Five biomarkers 
(GAL3, PAK2, PHB2, RACK1 and RUVBL1) were investigated in DCIS and 
node-negative early-stage breast cancer samples. The five markers significantly 
distinguished healthy controls from early-stage cancer with AUC of 0.81 and 
DCIS with AUC of 0.85 [118].   
1.3.4 Emerging Technologies for Profiling Antibody Responses 
Humoral response can provide us with important information about a 
person’s disease progression and overall health status. In order to get information 
about humoral response, we need high-throughput methods to profile an antibody 
repertoire in a patient at a given time. In order to do that, we need a large library 
of binding ligands to represent possible antigens. The ligand could be the real 
antigen, a peptide sequence representing the epitope, or a mimotope sharing the 
same binding with a disease- specific antibody. Several technologies have been 
proposed in the past and are summarized below [119, 120]. 
1.3.4.1 SEREX 
The serological screening of recombinant cDNA library using phage 
display (SEREX) is as follows: lambda phages are used to display proteins from a 
recombinant cDNA library of interests and probed with sera of interest to select 
antigens with high binding interactions with antibodies in the sera. Michael 
Pfreundschuh and colleagues [121] first introduced SEREX to isolate tumor 
antigens that trigger a high-titer humoral response in cancer patients. More than 
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2700 immunogenic antigens have been identified by SEREX [120, 122, 123]. The 
methodology of SEREX includes three main steps: building a cDNA library; 
probing with sera; and iteratively selecting sub-clones of phages.  
Building the cDNA library: The cDNA library is generated by reverse 
transcription of RNA from tissues or cell lines of interest. After the reverse 
transcription, all cDNA is inserted into constructed lambda phage vectors. After 
plating phages and transfer onto a nitrocellulose membrane, proteins will be 
expressed in an E. coli expression system.  
Probing with sera: Phage clones will be probed with diluted serum 
samples from cancer patients and proper controls. High-binding clones will be 
detected by an antibody-coupled enzymatic reaction and selected to be sequenced. 
Normally, candidates will be validated by independent methods such as ELISA or 
microarray.  
SEREX has been used to identify tumor-associated antigens (TAA) NY-
BR-1 to NY-BR-7 [124] and p33ING1[125] in breast cancer; NY-CO-37 and NY-
CO-38 in colon cancer [126]; NY-ESO-1 and SSX2 in esophageal cancer and 
melanoma [127, 128]; and NY-ESO-1, LAGE-1, and XAGE-1[129] in prostate 
cancer.  
Although SEREX has been used to discover thousands of tumor-
associated antigens, it has internal limitations. First, a large serum volume is 
required to screen for specific phage clones due to the extensive screening. 
However, many historical sample databases have only limited aliquots of each 
patient’s sample. Second, SEREX is biased to high-expression mRNA—a limit 
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that is internally inherent from its beginning. As we recall from its definition, 
SEREX aims to select antigens with high-binding interactions with antibodies in 
the sera. Although the cDNA library could have as many as 106 copies of phages, 
the constructed cDNA library will overrepresent the reverse transcriptions of 
those mRNA with a high expression level. When cancer-associated antigens are 
expressed at a lower level, those that are important indicators in early-stage will 
be substantially diluted and not even be represented during the screening. Third, 
because SEREX uses prokaryotic expression library, the structure of the antigens 
may not be correct—e.g., unnatural folding and post-translational modification. 
This will lead SEREX to miss some TAA and to an increased false-positive rate.  
Finally, the decrease in amount of an antibody will not be picked up by this 
system, which could also be as biomarker for diagnosis.   
1.3.4.2 Peptide and Peptoid Microarrays 
Peptide microarrays are comparable to SEREX in that they both use a 
large library of short peptide sequences. However, peptide microarrays overcome 
the bias of high-expression mRNA and the large volume of serum required in 
SEREX.  The core of peptide microarrays is a high-throughput way to display a 
large library of peptides with different sequences. Peptides can be chemically 
synthesized in large quantities in advance, and pure products are then linked to 
microarrays. This gives the peptide library a long shelf life. Sigma-
Genosys provides a synthesis platform to allow the rapid parallel synthesis of 
custom libraries. Peptides can also be directly generated in situ[130]. More than 
330,000 peptides can be generated on silicon wafers per assay, using 
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semiconductor manufacturing technology. Diluted serum samples will be probed 
on peptide microarrays, and the signal will be collected by labeled secondary 
antibodies with dye.  
Peptide microarrays have been used to study cell interaction[131], binding 
sequences of antibodies [132], enzymes [133, 134], proteins [135], and DNA and 
small molecules [136-138]. One important focus of peptide microarrays is on 
epitope mapping. Tiled peptide sequences with partial overlaps reveal the epitope 
of a monoclonal antibody [139]. The immunosignature section of this paper will 
include a more-detailed analysis of peptide microarrays.  
Other non-natural molecules can also be used for antibody profiling. One 
example is peptoid, a small molecule of N-substituted oligoglycines [140]. A 
peptoid microarray is constructed to display thousands of peptoids reproducibly 
on a chemically functionalized glass surface [141]. Diluted serum samples are 
probed on peptoid microarrays, and the signal will be collected by a labeled 
secondary antibody with dye. Muralidhar Reddy and his colleagues have shown 
the application of peptoid microarrays in their discovery of two candidate IgG 
biomarkers for Alzheimer’s disease [140].   
1.3.4.3 SERPA 
Serological proteomic analysis (SERPA) uses a different approach to 
overcome problems in peptides or protein synthesis. SERPA takes advantage of 
two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) and mass 
spectrometry analyses. Instead of using chemically synthesized peptides or 
expressed proteins to mimic antigens in the patients’ samples, SERPA directly 
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uses cell lines or tissue lysates. It first separates proteins in the samples by their 
isoelectric point and then further separates them by molecular mass in 2D-PAGE. 
The separated proteins are transferred onto membranes and then are probed with 
patient or control serum samples. The corresponding blot will be extracted from 
the 2D-PAGE and identified by mass spectrometry. SERPA overcomes some of 
the major limitations of other platforms, such as how to ensure a correct protein 
structure. But unlike other methods using microarray, it lacks the ability to 
perform high-throughput screening[142] and also requires a large number of 
serum samples [143]. 
1.3.4.4 Protein microarray 
The definition of a protein microarray is the technology that displays an 
array of proteins on a slide surface in a reproducible and addressable manner. The 
binding of each protein can be analyzed in a high-throughput way. Roger Ekins 
first introduced the concept of the protein array in 1989 [144], and MacBeath et al. 
developed the first mature protein array in 2000 [145]. Heng Zhu and his 
colleagues also printed protein arrays with 5,800 yeast proteins on a slide in 2002 
[146].  
Protein microarray can be divided into three categories: analytical protein 
array, reverse-phase protein array and functional protein array. Analytical protein 
arrays use antibodies printed on the array surface to capture proteins labeled with 
fluorescence in cell lysate [147]. Reverse-phase protein arrays, on the contrary, 
print cell lysate on a glass surface and probe proteins in cell lysate with 
fluorescence-labeled antibodies of interest. This platform requires high-quality 
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antibodies to achieve reliable results. Functional protein arrays aim to investigate 
the biochemistry properties and interactions of proteins with their targets, such as 
protein, DNA, RNA, drug, and enzyme. In a functional protein array, proteins are 
synthesized by a protein expression system and then spotted on the array surface 
or directly synthesized on the array surface. Cell-based expression systems 
include bacteria, insect cells or yeast, as well as the in-vitro expression system 
[145, 146, 148-150]. A widely used human protein microarray is Protoarray®, 
manufactured by Thermo Scientific [151]. In order to represent the correct protein 
structure, Protoarray uses the Sf9 insect cell line, which is the close to the 
mammalian expression system.  
Protein microarrays have been used extensively to profile humoral 
response to diseases and to screen for disease-specific autoantibody biomarkers 
[152-157]. 
Although thousands of tumor-associated antigens have been discovered 
using the protein microarray, it also has limitations. First, because proteins need 
to have the correct structure and be purified to ensure high-quality proteins that 
can be spotted on arrays, much effort is required to express the proteins correctly 
and to isolate and purify proteins from the expression system mix [158]. Post-
translational modifications may not be represented. Second, after collecting pure 
proteins, storage is a big issue. Proteins have only a limited shelf life and may 
aggregate or even become denatured after a few weeks. This will influence any 
functional study or protein-antibody bindings that require conformational epitopes 
[159]. A cell-free in situ expression system, Nucleic Acid Programmable Protein 
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Array (NAPPA), has been proposed to address these two problems [148]. Proteins 
will first be encoded by plasmids with a fusion tag and spotted on an array surface. 
After being expressed through a cell-free expression system, proteins will be 
captured by an affinity reagent in situ. However, some steps will still be required: 
building a plasmid system; inserting each protein into plasmids; and printing each 
plasmid to each spot on the microarray. Before probing with sera, proteins on a 
NAPPA array need to be expressed by an in vitro expression system. In addition, 
these systems are expensive and do not lead themselves to high-throughput 
production so are primarily useful as discovery platforms.  
1.4 Immunosignature 
1.4.1 Definition of Immunosignature 
The immunosignature is the binding pattern of a complex mixture of 
antibodies. Immunosignature technology uses a peptide array with 10,000 spotted 
peptides selected without bias from a non-biological peptide sequence space 
(Figure 1.5). It can reflect a disease state or, more generally, the health status of 
an individual. Immunosignature is a multidimensional reflection of overall 
humoral immune response. It can serve as a universal diagnostic platform to 
detect and identify any disease with a significant antibody response.   
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Figure 1. 5: Principle of Immunosignature 
Left is the scan image of CIM 10K array. Right is the major steps in 
immunosignature. Diluted Serum samples are probed on arrays. Biotinylated anti-
mouse IgG (H+L) antibodies are incubated on arrays next. Bound secondary 
antibodies are visualized by Alexa Fluor-647 labeled streptavidin.  
 
1.4.1.1 Building a Complex Chemical Surface 
At the core of immunosignature technology is an array with 10,000 
random-sequence peptides spotted in an addressable, machine-readable fashion 
with 20-mer peptides.[160]   
A random number generator generated the peptides sequences. We 
designed the algorithm of the random number generator to evenly cover as many 
combinations of amino acid sequences, potentially epitopes, as possible. These 
peptide sequences were not based on protein sequences in nature. For the choice 
of amino acids, we included all natural amino acids except cysteine to synthesize 
10,000 peptides. Cysteine is used only on the C-terminus of each peptide to form 
a chemical link to the activated surface in an oriented manner. The sequence of 
peptides can be a true epitope of that antibody or a serve as a mimotope of the 
actual epitopes due to the cross-reactive properties of antibodies [161].   
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Each peptide was spotted to an array surface in an addressable manner, so 
the sequence of each spot is known. We spotted 10,000 peptides on an array to 
cover a substantial portion of the molecular recognition space of all circulating 
antibodies. The aim of this design is to provide chemical complexity on an array 
to allow an unbiased display of antibody binding.  
1.4.1.2 Probing Sera 
To generate an immunosignature, a drop of blood or serum (2ul) is diluted 
at 1:500 in buffer. At this dilution, essentially only the antibodies from the serum 
bind the surface.  The diluted serum is then applied to the 10,000 peptides array.   
After applying the diluted serum on an array, we incubate the array for one 
hour and then wash it to remove unbound antibodies. Antibodies that are bound to 
peptides are detected by a secondary antibody and fluorescence dye. The array is 
then washed, dried and scanned to determine the array’s antibody binding profile.  
Different secondary antibodies can be used for specific isotypes of interest, which 
could provide more layers of information about an individual’s immune status.  
1.4.1.3 Analysis of Binding Pattern 
We read this pattern with our peptide microarray, which captures enough 
information about a patient that the health status is legible.  Once the arrays are 
probed with patient sera, the immunosignature of each disease state is determined 
by selecting peptides that show common reactivity among patients with the 
disease of interest and different reactivity in controls.  Selected peptides are used 
to train classification algorithms to evaluate diagnostic efficacy and classification 
error. 
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1.4.2 Advantage of Immunosignature 
As mentioned in the previous section, we can find the immunosignature 
that is unique to each disease and is stable over time [160]. The main reason for 
this advantage is that antibodies are stable in both circulating blood and stored 
sera samples. B cells that generated those antibodies can exist years after the 
immunogenic event has occurred, with a lifespan of up to four-and-a-half months 
[107, 108]. Moreover, after sera separation, antibodies are stable for several years 
in solutions [111, 112]. This means that we can use archived blood samples stored 
in sera or a standard filter spot [113].  
The random peptide array is universal.  We designed the algorithm of the 
random number generator to evenly cover as many combinations of amino acid 
sequences, potentially epitopes, as possible. These peptide sequences were not 
based on protein sequences in nature. The aim of this design is to provide 
chemical complexity on an array to allow an unbiased display of antibody binding. 
In this way, we can use same array to make diagnostic assays of other diseases or 
any condition that can be reflected in a circulating antibody repertoire.  
Immunosignature technology also does not require pre-knowledge of a 
complex disease. Unlike PCR, ELISA and protein arrays that require isolation of 
molecular targets to form an assay, we use random peptide sequences instead of 
known protein or epitope information. We can investigate diseases even if we do 
not known their antigens. The sequence of a peptide can be a true epitope of that 
antibody or serve as a mimotope of the actual epitopes due to the cross-reactive 
properties of antibodies [161]. We have shown that antibodies generated against 
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multiple types of targets, such as proteins and sugar, can bind peptides on the 
array [162]. This gives immunosignature the advantage of dealing with an 
outbreak of an unknown pathogen, and we can use same array for other diseases 
in different species. Although the peptide sequences are randomly generated, we 
can “decipher” diseases’ specific immunosignature based on sequencing analysis 
to guide us find real epitopes at times [163, 164].  
Immunosignature technology can be adapted to have multiple antibody 
isotypes measured simultaneously on an array. This will provide orthogonal 
measurements of a disease. Studies have shown that multiple isotypes can 
increase diagnostic performance [19, 109, 110, 113, 160]. We have also routinely 
detected both IgG and IgM on the same array in other studies.  
Because the immunosignature measures a host’s humoral response to a 
disease, we can evaluate how the host’s immune system responds to that disease. 
Some patients may have a high titer of protective antibodies and may not need 
any treatment later. We can use immunosignature technology to identify those 
patients and devote limited medical resources to the highly vulnerable patients 
who need treatment.  
In addition, the arrays are inexpensive and can be used to assay large 
numbers of samples quickly. 
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1.4.3 Published Studies with Immunosignature 
Immunosignature has been demonstrated in multiple diseases (infectious 
and chronic) or immunizations and in animal models (multiple mouse models), 
dog and human samples. We have demonstrated that the resulting 
immunosignature is unique for each disease that we tested and is stable over time 
[110, 160, 165-173].   
Take valley fever (Coccidioidomycosis) as an example of an infectious 
disease. We have demonstrated that by using a training set from 55 infected 
individuals and 55 uninfected individuals, we can achieve 100% prediction 
accuracy in an independent testing set. The immunosignature can detect the 
disease in samples from patients at a point in time when the standard ELISA test 
shows no titer, but the patient later develops valley fever[174].  
Also in chronic diseases such as cancers, immunosignature can detect the 
cancer- specific signature for each type of cancer. We have used a training cohort 
with five cancers (20 samples for each cancer) and 20 non-cancer samples to 
generate reference immunosignatures to distinguish each disease. The 
immunosignatures gave 95% classification accuracy in a blinded test with 120 
blinded samples with the same disease structure [175].  
In Alzheimer’s disease, Lucas Restrepo has developed immunosignature 
to detect the disease in both mouse-model and human samples[169]. 
1.5 Breast Cancer Treatment 
1.5.1 Clinical Treatment of Breast Cancer 
 
 37 
Current clinical breast cancer treatment includes three main methods: 
surgery, radiation, and drug treatment, including chemotherapy, hormone therapy, 
and targeted therapy. More recently, great achievements have been made in 
cancer immunotherapy, which may become an important part of future cancer 
treatment. Adjuvant therapy is a way of providing patients with more treatment 
after surgical removal of cancers. Neoadjuvant therapy is different in that a 
systemic treatment or radiation is giving before surgery to decrease tumor size.  
Healthcare professionals and medical researchers have investigated many 
different strategies for cancer treatment, and a combination of different treatments 
instead of a single one is the trend in the future.  
1.5.1.1 Surgery and Radiotherapy 
Removing the tumor through surgery remains the major way that breast 
cancer is treated. Surgery for cancer has been performed since the early 19th 
century and was later combined with anesthesia and antisepsis in the following 
half century. Surgery remained the only option before the appearance of radiation 
by the middle of the 20th century.  
The purpose of surgery is to remove as much of the cancer from a patient 
as possible. By using imaging technology, more-accurate surgery can be 
performed to almost completely remove the cancer cells and preserve the healthy 
tissues. Based on tumor size, extent of spread and the patient’s preference, 
different surgeries can be performed.  
Breast-conserving surgery (BCS): BCS, also called partial mastectomy, 
removes only a part of the breast, depending on the size and place of the tumor 
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and others. The removed breast tissue will be examined to see whether the tumor 
has spread to the edges. If it has, more surgery is needed to completely remove all 
tumor tissues. BCS is often followed by radiation to kill any remaining tumor 
cells.  
Mastectomy is a surgery that removes the entire breast and, sometimes, 
nearby tissue. If only the breast is removed, it is called a simple mastectomy. 
When a simple mastectomy is combined with an axillary lymph node dissection, 
it becomes a modified radical mastectomy.  Axillary lymph nodes will be 
examined for any tumor cells. A sentinel lymph node biopsy examines the first 
lymph nodes to which cancer may spread. Studies have shown that for early non-
invasive breast cancers, long-term survival is similar between BSC with radiation 
and mastectomy.  
The discovery of X-ray in 1895 by Wilhelm Roentgen made cancer 
radiation therapy possible. Radiation therapy uses high-energy rays such as x-rays 
or particles to kill cancer cells and shrink tumor size in the human body. External 
beam radiation uses a machine outside of the body to emit radiation. 
Brachytherapy is the placement of radioactive pellets into the breast tissue to kill 
targeted tumor tissues. Its long-term results may not be as good as those with 
external beam radiation. With the development of better radiation machines and 
computer imaging technology, radiotherapy developed significantly during the 
20th century. This contributed to a 30% increase in the cancer cure rate in in the 
1950s, when radiotherapy was combined with surgery [176]. 
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1.5.1.2 Cancer Drugs 
Besides surgery and radiotherapy, breast cancer treatment can also use 
drugs to kill cancer, including chemotherapy, hormone therapy, and targeted 
therapy. These drugs can be used to prevent cancer or treat diagnosed cancer. 
1.5.1.2.1 Chemotherapy 
Chemotherapy is the use of cancer-killing drugs. Drugs enter the human 
body and spread to different organs by blood circulation. Chemotherapy can be 
used before or after surgery for early-stage breast cancer. When chemotherapy is 
performed before surgery, it can shrink tumor size so that only BCS is needed 
instead of mastectomy. It can also decrease the risk of recurrence after surgery. 
 Chemotherapy is given in cycles, with each cycle of a treatment followed by a 
rest period. For early-stage breast cancer, a normal course of treatment may last 
for three to six months. However, if necessary, the chemotherapy can be 
continued as long as it is effective.  
After the use of chemotherapy in curing childhood leukemia and advanced 
Hodgkin’s lymphoma in the 1960s [177, 178], more drugs were discovered to 
treat major types of cancer. Chemotherapy has greatly improved patients’ 
outcome. However, chemotherapy has side effects, including menstrual changes, 
nerve damage, heart damage, nausea, hair loss and others. Because chemotherapy 
does not specifically target tumor cells, it will also affect normal cells.  Diagnostic 
tests have been developed to determine which patients will benefit most from 
chemotherapy. MammaPrint is a gene expression assay by Agendia to detect a 70-
genes profile by reverse-transcriptase PCR. It uses 117 patients with axillary 
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lymph node-negative primary breast cancer to find genes highly correlated with a 
short interval from primary tumor to distant metastases. MammaPrint profiling 
can help doctors to identify the sub-population of patients that will benefit most 
from chemotherapy [50].  
1.5.1.2.2 Hormone Therapy 
Hormone receptors—such as those for estrogen and progesterone—are on 
the surface of cancer cells. They promote the growth of the cancer. Hormone 
therapy works by blocking the hormone receptors in the receptor-positive tumor 
cells. It has been used to reduce the risk of recurrence after surgery and to treat 
advanced breast cancer. Hormone therapy may include tamoxifen, toremifene, 
and fulvestrant, which are estrogen blockers. Anastrozole, exemestane, and 
letrozole are aromatase inhibitors.  Hormonal therapy is beneficial for women 
with early-stage breast cancer that is positive for hormone receptors.  A diagnostic 
assay has been developed to identify the subpopulation of patients that benefit 
most from hormone therapy. Oncotype DX detects a 21-gene profile by reverse-
transcriptase PCR to predict the risk of recurrence in patients taking tamoxifen. 
Sixteen of the 21 genes are cancer-related genes with reference genes as reference. 
A mathematical algorithm is derived from an empirical retrospective study to 
calculate a score to estimate the risk of distant recurrence [49]. 
1.5.1.2.3 Targeted Therapy 
Specific genes targets have been found to promote breast cancer 
development. New drugs that specifically target those candidates are called 
targeted therapy. Trastuzumab, lapatinib and pertuzumab are targeted drugs that 
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are available to treated women with breast cancer overexpressing the growth-
promoting protein HER2. Most of these drugs are humanized monoclonal 
antibody or small-molecule kinase inhibitors that bind to different epitopes on the 
extracellular domain of HER2 receptors and inhibit its dimerization. Because 
tumor growth requires blood vessel formation to supply nutrition, anti-
angiogenesis drugs that prevent blood vessel growth in breast cancer are also 
tested in clinical trials. Chemotherapy, hormone therapy and targeted therapy 
have improved many patients’ outcomes. However, the problem is that after the 
primary tumor has been killed, the remaining sub-population of cancer cells will 
develop resistance to the initial treatment and can result in recurrence.  
1.5.2 Emerging Strategy of Immune Checkpoint Blockade 
The immune system in our bodies protects us from pathogens and 
abnormal conditions. In the immune-editing theory, immune surveillance inhibits 
tumor development from tumor initiation, and the tumor evolves through multiple 
mechanisms to avoid immune system surveillance [86, 87]. Much effort has been 
devoted to leverage immune system to fight against disease. 
William Coley performed the first clinical trial of cancer immunotherapy 
in 1891—Coley’s toxins. It was used to treat erysipelas with live or attenuated 
bacteria [179]. However, the efficacy of Coley’s toxins was controversial. Other 
immunotherapy drugs have been developed to target cancer-associated proteins 
and to induce tumor cell apoptosis, phagocytosis and antibody-dependent cellular 
cytotoxicity. These will trigger the adaptive immune system to target cancer [180]. 
Immunotherapy using immune checkpoint inhibitors has been promising in recent 
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years.  Immune checkpoint inhibitor therapy is based on the biology of immune 
suppression of the immune system by tumor cells. One mechanism of immune-
editing and surveillance is that tumor cells can suppress immune surveillance. 
Tumors can express immune suppression factors that inhibit immune infiltration 
and recruit myeloid-derived suppressor cells (MDSCs) and Regulatory T cells 
(Tregs) to the local tumor environment to inhibit the normal function of immune 
cells[181-186]. This will result in apoptosis of activated anti-tumor immune cells 
and induce tolerance.  
Among those, Tregs play an important role in the battle between tumor 
cells and the immune system [187, 188]. Tregs constitutively express CTLA-4 
[189, 190], which bind to CD80 and CD86 on the surface of antigen-presenting 
cells (APCs). The binding of CTLA-4/CD80 or CD86 blocks the co-stimulatory 
signal transduction and results in immunosuppression (Figure 1.6) [191-193]. 
Inhibitory receptor programmed cell death 1 (PD-1) contributes to immune 
tolerance of self-antigens and is expressed in many tumor-infiltrating 
lymphocytes, such as natural killer cells, dendritic cells, activated monocytes, B 
cells and T cells [194].  
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Figure 1. 6: Introduction of CTLA-4 and PD-1 Treatment 
Figure adapted with permission from Merelli et al [195].  
 
The binding of PD-1/PD-L1 is an important mechanism to convey an 
inhibitory signal to T cells and let tumor cells evade the immune system (Figure 
1.7) [196, 197]. Many clinical trials using antibodies targeting PD-1 or PD-L1 
have shown promising results in improving the survival rate in human prostate 
cancer, melanoma, and breast cancer [198, 199]. Expression of programmed death 
ligand 1(PD-L1) has been found in different types of cancer, such as non-small 
cell lung carcinoma [200], esophageal cancer [201], pancreatic cancer [202] and 
breast cancer [203]. Ghebeh and colleagues reported that PD-L1 is expressed in 
34% of primary breast cancer samples but not in healthy controls. The expression 
level of PD-L1 is significantly correlated with grade 3 tumors [203, 204].  
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Figure 1. 7: Biology and Mechanism of Anti-PD-L1 Antibody Treatment 
Figure adapted with permission from Patient Resource LLC 
 
With a combination of different therapy methods and the discovery of 
novel therapies, the mortality rate of many types of cancer has decreased during 
the past decades. However, due to the complexity of metastasis and immune 
suppression in late stages, a diagnostic tool that can detect tumors early will 
provide more therapy options and eventually improve patients’ outcomes. 
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CHAPTER 2  
Early Detection Of Breast Cancer 
2.1 Introduction 
In the United States in 2014, 235,030 new breast cancer cases were 
diagnosed, and there were 40,430 breast cancer deaths, making breast cancer the 
second leading cause of death among females [205]. Currently, the standard 
diagnostic tool for breast cancer is mammography. However, with its low 
sensitivity and specificity and its limitation to a specific population, 
mammography detects only 70% of breast cancers [33, 36, 37, 53]. The five-year 
relative survival rate decreases from 100% to 22% when breast cancers are 
detected at stage 4 instead of stage 1 [206]. Therefore, there is an urgent need for 
early diagnosis of breast cancer, as it could improve disease outcome and be the 
key to decreasing the death rate from breast cancer. This study proposes a serum 
test called immunosignature to identify specific antibody signatures to diagnose 
breast cancer early.  
Serum proteins, circulating miRNAs, circulating tumor cells (CTCs) and 
glycan biomarkers have been investigated to discover breast cancer biomarkers to 
diagnose the disease [72, 207-210]. Current plasma protein biomarkers in the 
human proteome organization (HUPO) project are in the range of ug/ml to mg/ml 
and the concentration of target molecules shed from a small number of tumor 
cells into the blood is 104 fold too low to be detected by current technology [100-
102]. This situation is especially true in early-stage breast cancer, when only a 
small number of tumor cells initiate and secrete molecules. The challenge for the 
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foregoing approaches is the detection of low-abundance valuable biomarkers of 
early stage breast cancer.  
Circulating serum antibodies could provide a comprehensive reflection of 
patients ‘health status. Immunosurveillance of B cells and T cells begins in the 
early stage. Tumor-specific B cells can be activated and amplify the antibody 
level, making the detection of a minimal exposure of antigen at the early stage 
feasible. Pre-diagnostic antibodies have shown value in the early detection of 
human breast cancer [19, 211, 212]. Chapman and colleagues found an antibody 
response to six antigens (c-myc, p53, HER2, NY-ESO-1, BRCA2 and MUC1) in 
early-stage primary breast cancer patients, although with low sensitivity [213]. 
Different panels of biomarkers all proved that a tumor-specific antibody response 
exists in early-stage breast cancer, such as the carcinoma in situ stage [117, 118]. 
Multiple antibody-based approaches have been explored to leverage the specific 
amplification effect of the immune system in the early-stage breast cancer. 
Serological screening of the recombinant cDNA library (SEREX) uses phages to 
display proteins from a recombinant cDNA library of interests and probed with 
tumor patients’ sera of interest to select antigens with high binding interactions 
with tumor related antibodies in the sera [122, 125, 126]. Serological proteomic 
analysis (SERPA) separates proteins from cell lines or tissue lysates into spots by 
two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) [143]. Selected 
spots will be analyzed by mass-spectrometry to find protein biomarkers for breast 
cancer. Protein arrays printed with pre-synthesized recombinant proteins or 
directly synthesizing proteins by an in-vitro expression system can also be used to 
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screen autoantibodies biomarkers in a high-throughput way. However, SEREX 
and SERPA require large amounts of serum for profiling, and the initial 
construction of the cDNA library in SEREX can easily cause biased result. 
Proteins may not be folded and modified correctly in all three methods. More 
importantly, these approaches can detect only antibody responses that target a 
limited number of known proteins in each system. This cannot capture neo-
antigens by mutations or post-translational modification.  
Here, we propose an unbiased antibody profiling technology using high-
density peptide microarrays for the early detection of breast cancer. The 
technology, called immunosignature (ImS), uses a peptide array with 10,000 
spotted peptides selected without bias from a non-biological peptide sequence 
space. The assay consists of applying diluted sera to the array and then detecting 
the binding pattern of the primary antibody with a labeled secondary antibody. In 
previous work, we successfully used immunosignature technology to find 
antibody signatures in early-stage pancreatic cancer and Alzheimer’s disease in 
human patients [168, 175, 214] 
This murine model develops invasive mammary carcinomas and can 
recapitulate the morphologic, pathologic, and molecular features of human 
luminal breast cancer at many stages [9]. We hypothesize that the FVB/N neuN 
mouse model can recapitulate human humoral responses to breast cancer and 
provide insights into the dynamic antibody profile from the early to late stages of 
breast tumor development. It can test whether, in principle, immunosignature can 
detect early stage of cancer or not.  
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We have found immunosignatures of early stage tumors as early as 12 
weeks before the tumor is first palpable. The existence of different 
immunosignatures at different stages reflects the dynamic changes in the antibody 
profiles during tumor development. By using the immunosignature at each stage, 
we achieved high sensitivity and specificity by cross-validation in multiple 
classification methods. Applying the late-stage immunosignature to early-stage 
samples resulted in low-prediction performance. This implies that the late-stage 
tumor immunosignature cannot be used to develop the early-stage signature. This 
study could determine the potential application of immunosignature technology in 
preclinical diagnosis of early-stage breast cancer.    
2.2 Results 
2.2.1 HER2 Transgenic Mouse Model 
This study uses FVB/N neuN transgenic mice, a well-characterized murine 
model for HER2 breast cancer, to compare antibody profiles at different stages of 
breast cancer. Mice are engineered with neuN with an MMTV promoter that 
restricts the neuN gene from being expressed in mammary glands. We collected 
blood samples from 23 transgenic mice and ten wild-type mice aged 12 weeks to 
terminal age. The mice were examined every week for any tumor formation, and 
any tumors found were measured once a week. Among the 23 transgenic mice, 
the first tumor was detected, on average, at 33 weeks of age (Fig. 2.1a) with an 
average tumor size of 96.3 mm3. We defined the point in time when the first 
palpable tumor was found in a mouse to be window 0 week. A window is used to 
calculate intervals between a certain age and the age at which the mouse had the 
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first tumor detected. The phenotypes of tumors at different stages are well 
characterized into hyperplasia, dysplasia and carcinoma in situ, multiple foci of 
carcinoma in situ or small lobular carcinoma, and carcinoma. Studies from 
Boggio and Abe have shown a transition from normal mammary glands to 
hyperplasia around 8.6 to 15 weeks [23, 215]. Figure 1b shows the tumor growth 
curve of this mouse model. The average tumor size and its standard error are 
plotted against days after the first palpable tumor was detected. 
 
Figure 2. 1: Tumor Free and Tumor Growth Curve of FVB/N NeuN 
Transgenic Mouse Model 
23 FVB/N NeuN transgenic mice and 10 FVB/N wild type controls were 
monitored every week for any palpable tumor in mammary glands. The median 
tumor free time is at 33.1 weeks with an average tumor size of 96.3 mm3. 94.3% 
of FVB/N NeuN transgenic mice will develop palpable tumors in 47.6 weeks 
monitoring. 
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2.2.2 Scheme of Experiment Design 
Figure 2. 2: Scheme of Experiment Design 
 
The scheme of the early diagnosis of breast cancer was layout in Figure 
2.2. Serum samples from FVB/N transgenic mice and wild type controls were 
collected every two weeks during tumor development. Mice were palpated every 
week to find any tumor occurrence. Serum samples were categorized into four 
stages: ‘Stage-1’ for samples at 12 weeks before 1st tumor, ‘Stage-2’ for samples 
at 8 weeks before 1st tumor, ‘Stage-3’ for samples at 4 weeks before 1st tumor, 
‘Stage-4’ for samples at at 1st tumor. For each time point, transgenic mice were 
compared with age-matched wild type controls to find significant peptides that 
passed statistic test.  
 
Tumor measured every week, blood collected every 2wks
Healthy                                            Early stage                                     1st palpable tumor           
Stage 1 12 weeks before
Stage 2 8 weeks before
Stage 3 4 weeks before
Stage 4 1st tumor
Early stage Age matched
VS
Transgenic Wild Type
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2.2.3 Influence of Genetic Background on Tumor-specific Immunosignature 
In order determine the extent to which transgenes might affect the ImS, we 
compared a sample set of seven transgenic mice at 12 weeks and seven age-
matched wild-type controls. Principle component analysis of these samples did 
not reveal clustering by groups (Fig. 2.3a). Fig. 2b shown a Heatmap analysis of 
four transgenic mice and six wild-type controls at 12 weeks. Although transgenic 
and wild type mice were not mixed after hieratical clustering, the intensity of 833 
selected peptide did not show distinguishable pattern between two groups (Fig. 
2.3b). No peptides could differentiate the two groups by hypothesis test in this 
ten-sample set with a two-tail t-test with p value cut off at 0.05 (Fig. 2.3c). An 
independent sample set of seven transgenic mice and nine wild- type controls 
resulted in 37.5% accuracy using the top 833 peptides with the highest p value in 
the previous set of seven transgenic and seven control mice (Fig. 2.3d). We 
concluded that the ImS was not influenced by the transgenes before the tumor 
activated. 
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Figure 2. 3: Influence of Genetic Background on Immunosignature 
A) Principle component analysis of 7 transgenic and 7 wild type mice at 12 week 
age by all peptides. 
B) Heatmap of 4 Tg and 6 WT at 12 weeks age by 833 peptides with top p value 
by t-test without MCC. No distinguishable patterns between Tg and WT were 
observed.  
C) Hypothesis test of 4 Tg and 6 WT at 12 week age. No peptides pass T-test. 1% 
peptides have P<0.01. 0.5% have <1.3 fold change. 
D) Classification result by 7 Tg and 9 WT at 12 weeks age by 833 peptides with 
top p value by t-test without MCC gives 37.5% accuracy.  
Each colored square represents relative median intensity. Blue: low expression; 
Red: high expression; Yellow: average expression. Clustering using two-way 
unsupervised hierarchical clustering with distance as measurement of similarity in 
GeneSpring software. Intensity is median normalization, the classifier uses Naïve 
Bayes by Weka. 
2.2.4 Existence of Pre-tumor Immunosignature Prior to Tumor Palpation 
To test whether immunosignature technology can detect changes at the 
pre-palpable tumor stage, we used eight transgenic mice (two weeks before the 
first tumor) and eight wild-type mice samples. We were able to detect a 
significant difference in antibody binding of 51 peptides (p≤0.05 with Benjamin 
and Hochberg FDR) between the transgenic and wild-type samples (Fig. 2.4a). 
The 51 peptides signature was further validated using an independent set of 
samples, including eight transgenic and eight wild-type mice. By using K-means 
to classify, the 51 peptides gave 100% sensitivity and 66.7% specificity (Fig. 
2.4b). Two experiments with different peptide libraries and samples all showed 
Tg WT
A CB
D
P value cutoff 0.05 0.02 0.01
T-test FDR 0 0 0
T-test Bonferroni 0 0 0
Tg(Predict) WT(Predict)
Tg (True) 0 7
WT (True) 3 6
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that significant peptides could be found between pre-tumor transgenic samples 
and wild-type controls. The average age of these pre-tumor samples were greater 
than 17 weeks, at which time the mammary glands had already progressed into 
carcinoma in situ. We concluded we can use immunosignatures to segregate 
transgenic and wild-type mice before the first palpable tumor was detected.  
Figure 2. 4: Immunosignature Can Show a Separation between Transgenic 
Mice and Age Matched Controls Two Weeks before First Palpable Tumor 
A) Independent sample sets with 8 transgenic mice (2 weeks before 1st tumor) 
and 8 wild type mice samples using CIM 10K Version 3 peptide library. 51 
peptides (p≤0.05 with Benjamin and Hochberg FDR) were significant between 
transgenic and wild type samples. Principle component analysis shows separation.  
B) Cross validation result of training sample and prediction performance in an 
independent samples gives a sensitivity of 87.5% (7 right in 8 cases) and 
specificity of 87.5% (7 right in 8 cases). 
2.2.5 Earliest Time Point of the Detectable Immunosignature  
After showing the existence of immunosignature at two weeks before first 
palpable tumor, we were interested in how early immunosignature could detect 
tumor. In order to test this, we used mice at 12 weeks, and 16 weeks to estimate 
the earliest time point in CIM-Version 2 arrays. Four transgenic and seven wild 
type mice at age of 12 weeks were ran in the same batch of slides (Fig. 2.5). No 
 
Cross validation Result
Sensitivity 87.5%
Specificity 87.5%
Independent
validation
Result
Sensitivity 100.0%
Specificity 66.7%
A
B
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peptide passed T-test with p value cutoff at 0.05. At age of 16 weeks, fifty three 
peptides were significant between five transgenic and seven wild type mice. The 
lack of difference between transgenic mice and wild type control at age of 12 
weeks and existence of significant difference at age of 16 weeks implied the 
earliest detectable time point for breast tumor is between 12 to 16 weeks by 
immunosignature in CIM-Version 2 arrays.  
Figure 2. 5: Heatmap of Immunosignatures of Different Time Points in 
Tumor Development 
Four NeuT transgenic FVB/N (Tg) mice and seven wild type FVB/N (WT) mice 
are assayed at age of 12 weeks and 16 weeks. Each colored square represents 
relative median intensity. Blue: low expression; Red: high expression; Yellow: 
average expression.  
2.2.6 Time Course of Immunosignatures During Tumor Progression in 
FVB/N neuN Mice 
Previous studies have shown that tumors present different tumor antigens 
at different stages [86, 87]. Also, biomarkers that were selected using late-stage 
patients gave poor prognostic performance in an early-stage setting. These facts 
imply that the immune system develops different antibody profiles along with the 
Tg
WT
11.4 Age of weeks 16.6
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development of a tumor. The immunosignature is a representation of the antibody 
profile at a given point in time. Therefore, we were interested in comparing 
immunosignatures from different stages to quantitatively investigate differences 
in antibody profiles. In this experiment, we selected 23 transgenic mice with ten 
wild-type controls from previous populations and collected serum at multiple 
points in time. Both the transgenic and control samples were grouped into four 
stages by the numbers of weeks before the first palpable tumor. We defined ‘IS-1’ 
as 12 weeks before the first tumor; ‘IS-2’ as eight weeks before the first tumor; 
‘IS-3’ as four weeks before the first tumor; and ‘IS-4’ as the time of the first 
tumor. Wild-type mice (aged 15.3 to 45.4 weeks) were used to make between-
stage comparisons comparable and to eliminate age influence.  
By using 23 transgenic mice and ten wild-type controls, we selected the 
top 200 significant peptides using an FDR-corrected T-test with a larger than 1.3-
fold change between transgenic and wild-type mice for each point in time (Fig 
2.6). To visualize the differences between transgenic mice and the wild-type 
controls, we plotted heatmaps containing these top 200 peptides between the 
transgenic and wild-type groups.  
We observed a change in immunosignatures from a greater to a less 
signature difference between the wild-type and transgenic mice from early to late 
stage tumors (Fig 2.6). This demonstrates that immunosignature can capture 
tumor development. The IS-1 heatmap showed two clear clusters of transgenic 
and wild-type mice. The majority of the peptides were highly reactive in the wild-
type controls and low reactive in the transgenic mice. This pattern reversed in IS-
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2, when the majority of peptide intensities were higher in transgenic mice. In IS-3 
and IS-4, the wild-type mice began to be clustered into the transgenic group. 
Distinguishing patterns of peptides intensities in transgenic and wild- type mice 
became less obvious in later stages of the tumor, while small clusters in these two 
groups appeared instead.  
Figure 2. 6: Time Course of Immunosignatures during Tumor Progression in 
FVB/N NeuN Mice 
23 NeuT transgenic FVB/N (Tg) mice are assayed at four time points- 12, 8, 4 
weeks before the first tumor and at the first tumor. 10 wild type FVB/N (WT) 
mice are assayed. We select the top 200 most significant peptides using FDR-
corrected T-test for each time point. Heatmap and PCA using each stage 
signatures are used to show the difference between transgenic mice and wild-type 
controls. Significant peptides are judged by p<=0.05 with fold change >=1.3. 
Each colored square represents relative median intensity. Blue: low expression; 
Red: high expression  
 
The Venn diagrams show the overlap of immunosignatures at the four 
stages (Fig. 2.7). We found that different tumor stages have different and partially 
overlapping signatures. The adjacent stages share more peptide overlap (Fig. 2.8). 
 
Tg WT
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The immunosignatures of IS-1 and IS-2 shared 25 peptides. The 
immunosignatures of IS-2 and IS-3 shared 35 peptides, while the 
immunosignatures of IS-3 and IS-4 shared 90. Sixteen peptides were shared by all 
four stages. These numbers are larger than the overlaps expected by peptides 
chosen at random. The number of overlapping peptides between the earliest stages 
(IS-1) and all the following stages remained consistent, but the number increased 
when comparing the latest stage (IS-4) with all the previous stages (Fig. 2.9). 
Taken together, this also shows that immunosignature can detect differences 
between transgenic mice and healthy control mice caused by tumor development 
at multiple stages.  
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Figure 2. 7: Venn Diagram of Different Immunosignatures Along Tumor 
Development 
Different stages in tumor development have different immunosignatures, a 
potential reflection of antigens profile changes by immunoediting in tumor 
development. 200 significant peptides with highest fold change between 
transgenic and control group are selected at four stages, corresponding to 12 
weeks before, 8 weeks before, 4 weeks before and at 1st tumor. Peptides shared 
among 4 stages take <10% in any stage.   
Figure 2. 8: Numbers of Selected Peptides Overlap between Two Adjacent 
Stages during Tumor Development 
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Figure 2. 9: Numbers of Selected Peptides Overlap between Earliest Tumor 
Signature with Other Stages Signatures 
2.2.7 Cross-stage Prediction 
Recent biomarker failures implied that using late-stage biomarkers for 
early prediction leads to low performance. Here, we tried to quantify cross-stage 
performance by using an immunosignature from one age to predict another. We 
use SVD in a PAMR package to predict twelve combinations of any two of the 
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four ages (Table 2.1). Using 200 peptides from IS-1 to predict IS-2, IS-3, and IS-4 
samples gave 0% accuracy. Using IS-2 to predict IS-1, IS-3, and IS-4 samples 
gave 0%, 4.2% and 8.3% accuracy, respectively. Using IS-3 to predict IS-1, IS-2, 
and IS-4 samples gave 28.6%, 58.3% and 87.5% accuracy, respectively. Using IS-
4 to predict IS-1, IS-2, and IS-3 samples gave 9.5%, 41.7% and 75.0% accuracy, 
respectively. This implies that late-stage tumor immunosignature cannot be used 
to develop an early-stage signature.  
Table 2. 1: Cross-Stage Prediction Performance in the Training Set 
Using peptides selected from 10 week before, 4 weeks before or 6 weeks after 
first tumor to predict samples from another time points. Accuracy is calculated by 
the percent of correct prediction of both transgenic and wild type mice in both 
groups. 
2.3 Methods 
2.3.1 Mice and Sample Collection 
Female FVB/NJ mice (n=10, age 6 weeks) were purchased from Jackson 
Laboratories (Bar Harbor, ME). Female FVB/N neuN transgenic mice were 
kindly gifted from Dr. Chella David at Mayo, Rochester. Transgenic FVB/N 
NeuN mice and wild-type FVB/NJ mice were maintained and weaned in the same 
barrier isolation housing with standard rodent feed and water. Mice were palpated 
every week to detect mammary tumor growth. Blood samples were collected by 
submandibular venipuncture using a 5.0 mm lancet (MEDIpoint, Inc. NY). Serum 
 
Accuracy -12 wks -8 wks -4 wks 1st tumor
-12wks to predict 0.0% 0.0% 0.0%
-8wks to predict 0.0% 4.2% 8.3%
-4wks to predict 28.6% 58.3% 87.5%
1st tumor to predict 9.5% 41.7% 75.0%
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was separated by serum separating Microtainer (BD Biosciences, San Jose, CA) 
and stored at -20 C with aliquots. Mice were euthanized by 2,2,2-tribromoethanol 
at a dose of 125mg/kg through intraperitoneal injection when tumor size exceeded 
10% of the body weight. All murine experiments were conducted following 
animal protocol reviewed and approved by Arizona State University Institutional 
Animal Care and Use Committee.  
2.3.2 Preparation of Microarray 
CIM10K peptide arrays were printed as earlier described [110, 160]. Two 
libraries of peptides were used separately: CIM10K Version 2 and Version 3. 
Both libraries contained 10,000 random 20-residue peptide of 17 random 
sequence amino acids. Peptides were designed with random sequences with 
nineteen amino acids (cysteine excluded), except for three residues at N-terminal 
as a linker to attach peptides covalently on Nexterion A+ aminosilane slides 
(Schott). The CIM10K Version 2 library contained L amino acid with Gly-Ser-
Cys-NH2 linker. Version 3 contained both L and D amino acids with Cys-Ser-
Gly-NH2 linker. Peptides were synthesized by Sigma Genosys (St. Louis, MO). 
Slides were printed using the two-up format by piezoelectric non-contact printer 
at Applied Microarrys (Tempe, AZ). Quality-control tests were performed using 
subsamples of each batch with pooled human naïve serum to select high array-to-
array correlation and dynamic range. After being produced, arrays were stored in 
containers, protected from light.  
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2.3.3 Probing Serum Antibodies on Peptide Microarrays 
Slides were first washed by 33% isopropanol, 7.5% acetonitrile, and 0.5% 
trifluoroacetic acid for five minutes, then dried by centrifuge at 800 rpm for five 
minutes. After pre-wash, slide processing was automated by a TECAN HS4800-
Pro automated incubator, following a protocol optimized for antibody binding. 
Briefly, arrays were blocking by 0.014% mercaptohexanol, 3% BSA, and 0.05% 
Tween 20 in 1×PBS solution for 1 h at 23° C. Serum samples were then diluted at 
1:500 in incubation buffer (3% BSA 0.05% Tween 20 in 1×PBS) and probed on 
arrays for one hour at 37° C. Biotinylated anti-mouse IgG(H+L) antibodies 
(Bethyl Laboratories, Montgomery, TX) were diluted in the incubation buffer at 
5nM for one hour at 37° C. Bound secondary antibodies were visualized by Alexa 
Fluor-647 labeled streptavidin (Invitrogen, CA) at 5nM for one hour at 37° C. The 
injection volume of each step was 110 μl per array, and TBST solution was used 
to wash the array between steps. The final wash used TBST and distilled water to 
remove residual salt on slides.  Correlation for technical replicates less than 0.85 
were re-probed [175]. 
2.3.4 Microarray Data Processing 
After the final wash, slides were scanned by an Agilent C scanner at 
633nm emission (Agilent Technologies, CA) with 100% laser power and 100% 
PMT. Images were extracted by GenePix Pro 6.0 (Molecular Devices, Sunnyvale, 
CA) and saved as gpr files. Poor-quality peptide spots were excluded by flagging 
them as “absent” by visual inspection. Samples with Pearson correlation 
coefficient >0.85 among technical replicates were used. Raw data from gpr files 
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were collected and imported into GeneSpring GX 7.3 or R for later processing 
(Agilent Technologies, Palo Alto, CA). Data were normalized to the 50th 
percentile to minimize array- to-array variation. Signal intensities below 0.01 
were set to 0.01. Batch effects were adjusted by SVA algorithm with irw as 
adjustment method with 10 iterations. The biological group was used as a 
covariate in SVA.  
2.3.5 Statistical Analysis 
Statistical analyses were done using Genespring GX 7.3 (Agilent 
Technologies, Palo Alto, CA), R version 3.1.1, and JMP version 11. P-values 
were corrected for multiple testing by the Benjamin-Hochberg false discovery rate 
method. The Welch t test was used in R to select significant peptides with greater 
than 1.3-fold changes and p<0.05 between two groups. We used a support vector 
machine with settings including polynomial dot order at 1 and scaling order at 0 
for cross-validation and prediction. Packages used in R were sva, caret, e1071 
[216, 217].  
2.4 Discussion 
In this study, we questioned the feasibility of breast cancer early detection 
by immunosignature technology. In comparing transgenic mice and their non-
transgenic littermates, we found the tumor-specific immunosignature of 
significantly different peptides as early as 12 weeks before a tumor became 
palpable. We also tested four more time points at early stages between transgenic 
and wild-type groups and found the immunosignature of significant peptides for 
each stage during tumor development. Fewer than 10% of the peptides were 
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shared among four time points. Using early-stage immunosignature to predict 
later-stage sample results in low classification performance.  
Early detection of breast cancer has the advantage of giving patients early 
treatment intervention and improving their outcomes. In our previous work, we 
successfully used immunosignature technology to find early antibody signatures 
in Alzheimer’s disease in a mouse model [168]. Here, we wanted to test whether 
we could detect the immunosignature of the early stages of breast cancer. 
However, serum samples from the same cancer patients before and after clinical 
diagnosis are hard to get. It is difficult to study biomarkers of early-stage breast 
cancer without proper early-stage samples. The FVB/N neuN transgenic mouse 
model is a well-established model to study breast cancer. In order to cover 
samples at the early stages of tumors, we collected serum samples for each 
transgenic mouse at time points from zero to twelve weeks before the first 
palpable tumor—aged 12.36 to 45.4 weeks. In this mouse model, hyperplasia 
occurred at around 8.6 to 15 weeks [23, 215]. So, selected samples could have 
good coverage of early stage breast cancer. Samples at multiple time points were 
tested to see whether we could find the immunosignature that distinguishes 
transgenic mice from wild-type controls.  
In human clinical trials, Lu and colleagues showed that autoantibodies 
against HER2 and p53 can be detected by protein microarrays 150 days before a 
breast cancer diagnosis. Opstal-van Winden and colleagues also showed that 
breast cancer autoantibodies can be found in patients’ samples a median of 21.3 
months before diagnosis. These findings proved the feasibility of early diagnosis 
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of breast cancer. However, a few protein biomarkers that were discovered in late-
stage cancer were evaluated each time, and their samples did not cover a wide 
range of early-stage breast cancers in humans. Using the same mouse model, 
Jianning Mao and colleagues used serological screening of cDNA expression 
libraries to identify tumor-associated autoantibodies in serum one month prior to 
the development of a palpable tumor. Six proteins were selected [19]. They found 
that autoantibody responses of six proteins appeared in mice as early as 20-30 
weeks of age. In our study, the earliest time point at which we found a difference 
by immunosignature was between ages 12 and 16 weeks, which is still during the 
time of hyperplasia development in this mouse model. This found 
immunosignature is more sensitive to the detection of a minimal antibody 
response in early-stage breast cancer. Our study also used more time points to 
reflect antibody responses in early-stage breast cancer more comprehensively.  
When we compared immunosignatures at different stages, the early 
signature was quite different from the late one. Antibodies that specifically target 
antigens that emerge in the late stages do not exist at an earlier stage. Fewer than 
10% of the peptides overlapped the four stages.  34 significant peptides 
overlapped Stages Ⅰ and Ⅳ, while 90 peptides overlapped Stages Ⅲ and Ⅳ. This 
showed that the binding pattern of the extra 56 peptides had been generated since 
Stage Ⅲ. In our previous study of Alzheimer’s disease, we also found that the 
early-stage was different from the late-stage immunosignature. These findings 
support the immunoediting theory of new antigens generated by tumors during an 
active immunoediting process.  
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Several studies have shown that biomarkers discovered in established 
tumor patients did not predict well in the early detection of breast cancer. Lu and 
colleagues used eight antigens to detect breast cancer samples 150 days before 
diagnosis. HER2 and p53 among the eight antigens gave a ROC score of 0.6 and 
0.63, respectively. Opstal-van Winden and colleagues also showed that markers 
discovered in diagnostic samples might not be valid in pre-diagnostic samples. 
Here, we use late-stage immunosignature to predict early-stage samples, and the 
performance of cross-stage prediction decreased significantly compared with 
cross-validation within each stage. Our findings suggest that using biomarkers 
discovered in diagnostic samples may be not valid in pre-diagnostic samples. 
They further suggest the importance of using proper pre-diagnostic samples to 
discover early-detection biomarkers.  
In terms of intensity level, the majority of peptides in early breast cancer 
sera are less reactive than non-cancer controls. We hypothesize that the down 
regulation that of antibodies may be caused by immunosuppression. Edward Y. 
Woo and colleagues reported CD4+ CD25+ T cells secrete immunosuppressive 
cytokine transforming growth factor- β in early-stage non-small cell lung cancer 
[218]. In breast cancer, Isabel Poschke and colleagues observed 
immunosuppression in early-stage breast cancer patients in terms of the 
exhaustion of tumor-associated T cells [219]. A report also showed that Atypical 
T cell-suppressive neutrophils occurred during early tumor progression [220]. In 
terms of antibody response, data from Jianning Mao and colleagues showed a low 
reactivity of autoantibodies to four tumor-associated proteins in early-stage breast 
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cancer [19]. Our findings further showed that immunosuppression already occurs 
at early stages of tumor development in humoral response. 
We also observed that the immunosignature of transgenic mice is 
homogeneous among different mice at Stage Ⅰ but become sparsely distributed 
at later stages. Because the tumorigenesis of this mouse model is initiated by a 
single oncogene (NeuN) expression, the immune system in different mice may 
response in a similar way. However, when more mutations occur during tumor 
development, the immune system in each mouse will respond differently to new 
tumor antigens. At the scope of 12 weeks, the dramatic changes in the 
immunosignature imply that the immune system has gone through significant 
changes along with tumor development. 
We recognize that the limited sample size and the use of a random 
sequence array may not be the best conditions for finding gene and protein targets. 
Because serum from each mouse needed to be collected as the tumors developed, 
the tumor’s histology information could not be known. However, this study 
established the methodology and demonstrated the feasibility of early detection of 
breast cancer by immunosignature technology in a mouse model.  
Early detection of breast cancer could lead to early treatment intervention 
and improved patient outcomes. Future studies can use retrospective sample 
collections in clinical trials to develop a specific immunosignature for early-stage 
breast cancer in humans. If these immunosignatures are found, we could use 
multiple immunosignatures at different stages in early breast cancer to predict 
breast cancer early and reduce the false-positive rate in cancer prediction.    
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2.5 Supplements 
2.5.1 Selection of multiple batches of array 
Due to the large number of slides that were used in this study, slides from 
multiple batches of printing were selected. In order to reduce the variance caused 
by different printing of batches, we tested the correlation of the same quality 
control sample in eight different batches. Statistic characterization were also 
calculated to evaluate the overall performance for different batches, including 
intensity of empty spots on a slides, ratio of median intensity of all peptides to 
empty spots, coefficient of variance of all peptides, correlation between two 
technical replicates using same quality control samples (Table 2.2, table 2.3). 
From the analysis, batches from 474, 493, 494, 524,530,538 and 540 were 
selected.  
Table 2. 2: Correlation Analysis for Different Printing Batches of Slides 
Using Quality Control Sample 
First column and last row are the batch number. Square of Pearson Correlation is 
calculated for each comparison between eight different batches.  
 
474 0.464 0.441 0.420 0.428 0.385 0.292 0.188
486 0.570 0.360 0.325 0.288 0.248 0.130
493 0.615 0.584 0.532 0.400 0.225
494 0.855 0.837 0.638 0.324
524 0.928 0.613 0.318
530 0.688 0.354
538 0.477
540 486 493 494 524 530 538 540
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Table 2. 3: Statistic Characterization of Different Batches of Slides 
Correlation analysis for different printing batches of slides using quality control 
sample. Empty: intensity of empty spots on a slides; f647 M/E: ratio of median 
intensity of all peptides to empty spots; f647 CV: coefficient of variance of all 
peptides; Correlation: correlation between two technical replicates using same 
quality control samples. 
2.5.2 Removal of Batch Effect 
One important issue in microarray experiment is the variance caused by 
batch effect. In this experiment, seven different batches of slides were used. 
Principle Component Analysis (PCA) of 336 samples using all peptides with 
median normalization was plotted to illustrate batch effect (Figure 2.10). From the 
figure, we can see batch 474 and some samples in batch 493 were separated from 
other batches. Batch removal methods were needed to remove these difference 
from non-biological difference.  
Batch Empty f647 M/E f647 CV Correlation Printing date Slide Order 
474 1321.78 12.87 68.00% 0.95 5/18/2012 135 Schott A+ slides A1947
486 583.67 8.1 97.90% 0.9 5/29/2012 136 Schott A+ slides A1956
493 534.55 5.71 70.40% 0.87 6/7/2012 126 Schott A+ slides A1962
494 920.22 6.97 78.10% 0.92 6/13/2012 126 Schott A+ slides A1970
524 1646.39 7.72 66.50% 0.98 7/23/2012 136 Schott A+ slides A2002
530 1168.19 7.21 60.80% 0.96 7/27/2012 136 Schott A+ slides A2003
538 442.08 6.11 83.40% 0.92 8/1/2012 136 Schott A+ slides A2015
540 495.57 1.17 21.30% 0.56 8/3/2012 136 Schott A+ slides A2016
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 Figure 2. 10: Principle Component Analysis of Different Batches 
 
Our lab had employed ComBat to remove batch effects [221, 222] in 
previous studies. Surrogate variable analysis (SVA) is also a widely used batch 
effect removal method [217]. Batch removal methods need to be selected based 
for the specificity of different studies [223, 224]. Here, we evaluated SVA and 
ComBat methods in a data set from array result of 168 different mice sera samples 
each with two replicates (Fig 2.11, Fig 2.12, Fig 2.13). Packages from SVA and 
ComBat were run in R. Correlations between median normalized data and SVA or 
ComBat adjusted data for each sample were plotted. PCA was also plotted to 
show the variance between different batches after adjustment of batch effects. In 
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SVA, we can choose irw and twostep as different methods. I tested the irw 
method with 10 iterations and twostep method in SVA (Fig 2.11).  
 
Figure 2. 11: Correlation of Technical Replicates Before and After SVA 
Adjusted and PCA Analysis of Batch Effects 
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Figure 2. 12: Correlation of Technical Replicates Before and After Combat 
Adjusted and PCA Analysis of Batch Effects 
After both irw and twostep method in SVA, batch effects were largely reduced by 
the visualization of PCA. Correlation between technical replicates for the same 
sample increased. By comparing statistics of technical correlation after different 
SVA and ComBat, we found irw with 10 iterations in SVA package gave the best 
performance in both reducing batch effects and increasing correlation of technical 
replicates for the same samples (Figure 2.).  
Technical Correlation before ComBat Technical Correlation After ComBat
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Figure 2. 13: Comparison of Different Batch Effect Removal Methods 
Correlation of technical replicates for 168 samples after different batch effect 
removal methods are summarized.   
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CHAPTER 3  
A MODEL FOR THE EARLY DETECTION AND TREATMENT OF 
CANCER 
3.1 Abstract 
Cancer kills ~8M people/year and the WHO predicts an epidemic of 
cancer in the developing world over the next 20 years due to increased longevity. 
Development of a simple method to detect and treat cancer early could be a 
solution to this challenge.  Here we test this approach in principle in a mouse 
mammary tumor model.  We had previously demonstrated that tumors could be 
detected at an early stage in the mouse FVB-NeuN (MMTVneu/202Mul/J) 
mammary cancer model by immunosignature diagnostics. Immunosignatures are 
profiles of antibodies in the blood displayed on peptide arrays.  We determined if 
early treatment at the time of diagnosis with the checkpoint blockade, anti-PD-L1, 
would inhibit the tumor growth.  A course of 3 injections at the time of diagnosis 
significantly retarded tumor growth relative to untreated controls. The early 
treatment elicited long protection which could restrict the tumor growth even four 
months after the treatment. The treated mice share a specific immunosignature 28 
days post treatment and 28 days post the first palpable tumor, compared to the 
untreated mice. This indicates that the early treatment elicited an anti-tumor 
immune response that could inhibit tumor growth. This preliminary experiment 
suggests that early diagnosis combined with systemic treatment might be a 
method to control or eliminate cancer.  
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3.2 Introduction 
Since most of the deaths from cancer occur in the developing world, any 
solution to the cancer problem must be applicable to the whole world population.  
A possible solution is to develop a simple, inexpensive technique to detect cancer 
early and couple it to a systemic treatment that would eradicate the tumor.  Early 
detection and early treatment has the advantages that the tumor cell number is 
small, the chance for evolving evasive mutations is less and the probability of 
metastasis is greatly decreased.  It also is likely a lower dose and shorter treatment 
would be efficient, so the cost and side effect will be reduced.  
We developed the immunosignature diagnostic technology for the early 
detection of changes in health status, including early cancers [168, 175]. The 
technology is based on the peptide array with 10,000 spotted peptides. These 
peptides are disease agnostic as they are chosen from non-biological peptide 
sequence space [225]. The assay consists of applying diluted sera to the array and 
then detecting the binding pattern of primary antibody with a labeled secondary 
antibody. The technology relies on the activation of humoral immune response to 
diseased cells, such as nascent transformed cells. The humoral immune response 
changes antibody profile and can be detected by the immunosignature.  It has 
been used to detect multiple diseases.  We have shown that this technique can 
detect Alzheimer’s disease at an early stage in a mouse model [168] and recently 
showed that mammary tumors could be detected by this method at a very early 
stage in FVB-NeuN mice, a mouse mammary tumor model.  
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Immune checkpoint blockades are showing promise as systemic cancer 
therapeutics.  A portion, but not all, patients treated have demonstrated definitive 
responses [195].  The underlying concept is that an antitumor immune response is 
naturally mounted against any tumor but it is suppressed in multiple ways by the 
tumors cells directly (PD1, PD-L1) or through T-regulatory cells (CTLA4) [226].  
Checkpoint blockades release this suppression allowing the native antitumor 
response to limit or even kill the tumor cells. For example, anti-PD-L1 is an 
antibody therapeutic that has been reported to have efficacy in treatment of late 
stage melanoma and lung cancer.  To date, three such drugs have been approved 
by FDA. Many more human trials are in the progress. Patients in all clinical trials 
are at late stage disease [198, 199]. 
We proposed that combining early detection and a checkpoint inhibitor 
treatment (eg. anti-PD-L1) would be an effective way to treat tumors, before they 
were imageable or symptomatic.  The question is whether the immune response to 
a tumor at an early stage, even if unsuppressed, would be sufficient to inhibit the 
tumor. We tested this basic concept using a transgenic mouse model of breast 
cancer.  In the FVB-NeuN model the MMTV promoter activates the wild type rat 
ERBB2 gene in mammary cells, and every mammary cell potentially turns to be 
cancer cell. The mice develop 1-3 (2.7±0.33) tumors at 19-45 (32.6±1.2) weeks 
of age in our hand. Studies from Boggio and Abe using same mouse model have 
shown a transition from normal mammary glands to hyperplasia around 8.6 to 15 
weeks [23, 215]. We had previously demonstrated that an immunosignature of the 
initiation of the tumor could be detected at least 12 weeks before a palpable tumor. 
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We defined this signature as the early stage of the cancer, namely stage I 
signature. Here we ask whether checkpoint treatment by PD-L1 blockade can be 
effective at this early stage. 
3.3 Results:  
3.3.1 Early Detection of Breast Cancer and PD-L1 Treatment 
The basic outline of the experimental design is cartooned in Figure 1. 
Mice were monitored every four weeks for their immunosignature. The treatment 
was immediately initiated when a mouse was scored positive for the stage I 
cancer signature in two contiguous monitors. The summary heatmap of the 
confirmed stage I signature comparing to the historical data is given in Figure 3.1. 
The treatment consisted of 3 intraperitoneal injections of 200ug anti-PD-L1 
(10F.9G2) every three days. Serum was collected in four week intervals after 
treatment. The timeframe for occurrence of signatures, palpable tumor and 
treatments is given in Table 3.1. A group of 3 mice were not treated after the 
signature was identified.  The anti-PD-L1 antibody injection step was done by 
Luhui Shen. 
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Figure 3. 1: Cartoon of Experimental Design Outline 
Mice were monitored every four weeks for their immunosignature. The treatment 
was immediately initiated when a mouse was scored positive for the stage I 
cancer signature in two continue monitors. Treatment consisted of 3 injections of 
anti-PDl1 (10F.9G2) over 9 days. Serum was collected in four week intervals 
after treatment.   
Table 3. 1: The Timeframe for Occurrence of Signatures, Palpable Tumor 
and Treatments 
Sample from anti-PD-L1 treatment group and non-treated control are labeled in 
the rows. Columns are ages of mice at seven time points. “+” means samples at 
that time point scores positive for the stage I cancer signature. Green shows the 
 
Early detection                                      Drug treatment
Stage 1 Signature 
Positive
Stage 1 Signature 
Positive
0 days                                 +28 days                                   +37 days
3 inject α-PD-L1 Ab
 
Sample 16 wks 20 wks 24 wks 28 wks 32 wks 36 wks 40 wks
Treated #1 + - + + Tumor
Treated#2 + - + +
Treated#3 + +
Treated#4 + + Tumor
Treated#5 + + Tumor
Treated#6 + + Tumor
Treated#7 + - + + Tumor
Treated#8 + + Tumor
Treated#9 + +
Treated#10 + +
Non-treated#1 Tumor
Non-treated#2 Tumor
Non-treated#3 Tumor
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time point of giving the treatment. Red “Tumor” shows the time point of having 
first palpable tumor.  
 
3.3.2 Inhibition of Tumor Growth Rate by Early Treatment 
The tumor volumes were measured every week and plotted in Figure 3.2. 
As evident the PDL1 treatment had several effects.  Four of ten treated mice did 
not developed a palpable tumor at 40 weeks old. Tumor growth rate was 
significantly retarded in the treated mice that eventually developed tumors. This 
tumor growth inhibition was a long term protection. It was still effective to hinder 
the growth of tumors in the mice that started to develop a tumor 4 months after of 
the treatment. Tumors from the untreated controls and the treated mice were 
examined at the same time point after detection.  
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Figure 3. 2: Tumor Growth Characteristics in FVB/N neuN α-PD-L1 
Treatment Experiment 
The tumor volumes were measured every week and plotted. Tumor growth rate 
was significantly retarded in the α-PD-L1 treated mice that eventually developed 
tumors. Non-treated mice share same characteristics with historical non-treated 
mice. 
3.3.3 RNA Expression of PD-L1 in Mammary Glands 
PD- An implication of the effect of anti-PD-L1 treatment is that the gene 
is expressed in the early stage of tumor development.  To test this we performed 
an RNA analysis on mammary glands with normal morphology and established 
tumors with different size. (Figure 3.3).  The PD-L1 expression level was 
significantly higher in normal mammary glands than established tumors, 
especially in mammary gland with increasing expression of MMTV, which 
indicates the initiation of tumor development by increasing the expression of rat 
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ERBB2. The PD-L1 expression was decreased after the tumor was established. 
All of the tumors had similar expression level of PD-L1 regardless the size and 
expression level of rat ERBB2 (Figure 4). We concluded the L1 gene and 
presumably protein were expressed on mouse mammary cells and the expression 
was lower in established tumor.  
The RT-PCR step was done by Luhui Shen. 
Figure 3. 3: RT-PCR Analysis of MMTV Promotor and PDL1 Expression in 
Established Tumors and Adjacent Normal Mammary Glands in No-Treated 
FVB-Neun Mice 
RNA analysis on different stages of established tumors and mammary 
glands.   MMTV is the promotor of Rat Her2 gene in FVB-NeuN mouse. Both 
PDL1 and rat Her2 were at similar expression levels in different stages of the 
established tumors. PDL1 is express high in normal mg and decrease in tumor.  
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3.3.4 Changes of Immunosignatures After PD-L1 Treatment 
The long term protection of the short term early treatment suggested that 
the treatment elicited an efficient anti-tumor immune response. The immune 
checkpoint blockades can induce unique immunologic changes in cancer patients, 
which may be related to the anti-tumor immune response [227]. It is possible 
these changes are reflected in the antibody profiles. We found a specific 
immunosignature of 321 peptides that can distinguish the treated mice 28 days 
after the treatments with both the age matched untreated mice and their own 
signature before the treatment. The 321 peptides gave a separated clustering 
between the treated mice 28 days after the treatments PD-L1 and all samples 
without PD-L1 treatment at three time points (Figure 3.4a). The same 
immunosignature was also detected in the treated mice 28 days after treatment 
and 35 days after their first palpable tumors, compared with non-treated mice at 
age of 16 weeks (Figure 3.4b). In 46.4% selected peptides, their antibody 
activities were significantly increased after the tumor established. Taken together, 
this immunosignature suggests that the anti-tumor immune response was elicited 
in the treated mice for long term protection.   
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Figure 3. 4: Heatmap Showing PD-L1 Generated Immunosignature 
Sera were collected from 8 FVB neuN mice in the PD-L1 treatment group at 28 
days after the treatment (AT_T28), and at 35 days after 1st tumor (AT_F35). 8 
age-match transgenic controls without any treatment were also collected for sera 
at corresponding time points ( NT_T28, NT_F35). Sera were collected from all 
mice at age of 16 weeks (NT_Wk16) before any PD-L1 treatment. The 
immunosignature of 321 peptides selected distinguished samples of AT_T28 and 
NT_T28.  
A) Heatmap of selected peptides depicting simultaneous analysis of samples at 28 
days after the treatment (AT_T28) compared with samples without PD-L1 
treatment at 3 time points (NT_Wk16, NT_T28, NT_F35). 
B) Heatmap of selected peptides showing the immunosignatures at one time point 
without treatment (NT_Wk16) and two following time points with treatment 
(AT_T28, AT_F35) 
A B
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3.4 Methods 
3.4.1 Mice and Sample Collection 
Female FVB/NJ mice (n=10, age 6 weeks) were purchased from Jackson 
Laboratories (Barharbor, ME). Female FVB/N neuN transgenic mice were kindly 
gifted from Dr. Chella David at Mayo, Rochester. Transgenic FVB/N NeuN mice 
and wild-type FVB/NJ mice were maintained and weaned in the same barrier 
isolation housing with standard rodent feed and water. Mice were palpated every 
week to detect mammary tumor growth. Blood samples were collected by 
submandibular venipuncture using a 5.0 mm lancet (MEDIpoint, Inc. NY). Serum 
was separated by serum separating Microtainer (BD Biosciences, San Jose, CA) 
and stored at -20 C with aliquots. Mice were euthanized by 2,2,2-tribromoethanol 
at a dose of 125mg/kg through intraperitoneal injection when tumor size exceeded 
10% of the body weight. All murine experiments were conducted following 
animal protocol reviewed and approved by Arizona State University Institutional 
Animal Care and Use Committee. 
3.4.2 Binding of Sera to the Peptide Microarrays 
CIM10K Version 3 peptide arrays were printed as earlier described [110, 
160]. CIM10K Version 3 library contained 10,000 random 20-residue peptide of 
17 random sequence amino acids. Peptides were designed with random sequences 
with nineteen amino acids (cysteine excluded), except for three residues at N-
terminal as a linker to attach peptides covalently on Nexterion A+ aminosilane 
slides (Schott). Version 3 contained both L and D amino acids with Cys-Ser-Gly-
NH2 linker. Peptides were synthesized by Sigma Genosys (St. Louis, MO). Slides 
 85 
were printed using the two-up format by piezoelectric non-contact printer at 
Applied Microarrys (Tempe, AZ). Quality-control tests were performed using 
subsamples of each batch with pooled human naïve serum to select high array-to-
array correlation and dynamic range. After being produced, arrays were stored in 
containers, protected from light. 
Slides were first washed by 33% isopropanol, 7.5% acetonitrile, and 0.5% 
trifluoroacetic acid for five minutes, then dried by centrifuge at 800 rpm for five 
minutes. After pre-wash, slide processing was automated by a TECAN HS4800-
Pro automated incubator, following a protocol optimized for antibody binding. 
Briefly, arrays were blocking by 0.014% mercaptohexanol, 3% BSA, and 0.05% 
Tween 20 in 1×PBS solution for 1 h at 23° C. Serum samples were then diluted at 
1:500 in incubation buffer (3% BSA 0.05% Tween 20 in 1×PBS) and probed on 
arrays for one hour at 37° C. Biotinylated anti-mouse IgG(H+L) antibodies 
(Bethyl Laboratories, Montgomery, TX) were diluted in the incubation buffer at 
5nM for one hour at 37° C. Bound secondary antibodies were visualized by Alexa 
Fluor-647 labeled streptavidin (Invitrogen, CA) at 5nM for one hour at 37° C. The 
injection volume of each step was 110 μl per array, and TBST solution was used 
to wash the array between steps. The final wash used TBST and distilled water to 
remove residual salt on slides.  Correlation for technical replicates less than 0.85 
were re-probed [175]. 
3.4.3 PD-L1 Treatment Regime 
Stage I cancer signature of FVB/N-NeuN model was established in 
Chapter 2. The age when the mice showed the stage I signature was 16 weeks. 10 
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mice were start immunosignature analysis every four weeks since 16 weeks old. 
The mouse was confirmed with stage I cancer immunosignature in two continual 
analysis was treated 200ug anti-mouse PD-L1 antibody in PBS every three days 
through i.p. for total three treatments. Monoclonal anti mouse PD-L1 antibody 
(10F.9G2) were purchased from BioXcell (Cat#: BE0101). 
3.4.4 RNA Expression in Mammary Gland 
All tissues and tumor were collected and storage in RNA-later (Ambion, 
Cat#AM7020). Total RNA were purified with TRIzol (Life Tech. Cat#15596-018) 
and PureLink RNA purification system (Life Tech. Cat#12183-018). Genomic 
DNA were removed with PapidOut DNA Removal kit (Thermo Sci. Cat#K2981). 
cDNAs were synthesized from 2ug of total RNA from each sample with cDNA 
synthesis kit (Thermo Sci. Cat#K1641). PCR reactions were set up with PCR 
SuperMix (Life Tech. Cat#10572-014) in 20ul reaction volume. The expression of 
β-actin, PD-L1 and MMTV promotor (the promotor for Rat Her2 gene) were 
analyzed.  
PCR primers:  
β-actin: 5’:CCTGTATGCCTCTGGTCG;3’: TGTCACGCACGATTTCC. 
PDL1:5’:TTCACAGCCTGCTGTCACTT; 3’:GGGCATTGACTTTCAGCGTG. 
MMTV: 5’: ATCGGTGATGTCGGCGATAT; 3’:GTAACACAGGCAGATGT 
AGGA.  
PCR condition: β-actin: 95℃ 2’, (95℃ 30”, 60℃ 30”, 72℃ 30”) X 25 
cycles, 72℃ 5’. PDL1: 95℃ 2’, (95℃ 30”, 65℃ 30”, 72℃ 30”) X 27 cycles, 72℃ 
5’. CMV: 95℃ 2’ , (95℃ 30”, 60℃ 30”, 72℃ 30”) X 30 cycles, 72℃ 5’.  
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3.4.5 Statistical Analysis 
After the final wash, slides were scanned by an Agilent C scanner at 
633nm emission (Agilent Technologies, CA) with 100% laser power and 100% 
PMT. Images were extracted by GenePix Pro 6.0 (Molecular Devices, Sunnyvale, 
CA) and saved as gpr files. Poor-quality peptide spots were excluded by flagging 
them as “absent” by visual inspection. Samples with Pearson correlation 
coefficient >0.85 among technical replicates were used. Raw data from gpr files 
were collected and imported into R for later processing (Agilent Technologies, 
Palo Alto, CA). Data were normalized to the 50th percentile to minimize array- 
to-array variation. Batch effects were adjusted by SVA algorithm with irw as 
adjustment method with 10 iterations. The biological group was used as a 
covariate in SVA. Statistical analyses were done using R version 3.1.1, and JMP 
version 11. P-values were corrected for multiple testing by the Benjamin-
Hochberg false discovery rate method. The Welch t test was used in R to select 
significant peptides with greater than 1.3-fold changes and p<0.05 between two 
groups. We used a support vector machine with settings including polynomial dot 
order at 1 and scaling order at 0 for cross-validation and prediction. Packages 
used in R were sva, caret, e1071 [216, 217].  
3.5 Discussion 
We had shown that transgenic mice display an immunosignature of having 
a tumor at least 12 weeks before the tumor is palpable. Short treatment at this 
early stage with i.p. injection of anti-PD-L1 retarded the tumor growth compared 
to the untreated mice. This early treatment has long term protection, which can 
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slow the tumor growth four months after the treatment with similar efficiency in 
the mice that develop tumor late. High PD-L1 gene expression was evident in the 
transforming initiated mammary glands, consistent with the effects of anti-PD-L1 
treatment at early stages. The early treatment elicited a specific antibody profile 
which can be detected one month after the treatment and the first palpable tumor 
established in the treated mice.  
It was not obvious that early treatment of a tumor would be effective. It 
would depend first on the tumor actually producing PD-L1 at this early stage and 
second, that there is a potential anti-tumor immune response at the same time that 
was being inhibited by the PD1/PD-L1 immune checkpoint pathway. In other 
studies, higher mRNA expression of PD-L1 in the diagnosed tumor were 
observed in the patient’s tissue and also in multiple breast cancer cell lines [204, 
228-232]. Triple-negative breast cancer (TNBC), basal type breast cancer cells 
expressed higher levels of PD-L1 constitutively [228, 232]. Although subtypes of 
breast cancer can influence clinical treatment strategy, timing is also an important 
factor when giving treatments. However, few study investigate PD-L1 mRNA 
expression level at prediagnosed stage and its relationship between anti-PD-L1 
treatment effects. Here we demonstrated that PD-L1 was highly expressed in the 
early stage of the tumor when transformation was just initiated. 
The immune checkpoint blockade treatment in cancer patients could 
induce unique systemic immunologic changes [227], which are possible to elicit a 
long term anti-tumor immune response against tumor developing in different 
location. In the late stage cancer, increasing number of tumor-infiltrating 
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lymphocytes (TIL) in tumors were reported to be significantly correlated with 
anti-PD-L1 treatment [198, 199, 229]. Therefore, we hypothesize that for 
protection, one underline mechanism could be anti-PD-L1 treatment can also 
boost the immune system even at early stage by increasing tumor infiltration.  
The long term protection of the early treatment in this experiment 
indicates the anti-tumor immune responses were elicited and boosted by the 
treatment. This is supported by a specific and consistent immunosignature of the 
treated mice in both one month after the treatment and the first palpable tumor 
was established, comparing to the non-treated mice with matched age and tumor 
status. Also in multiple advanced human cancers, BMS-936559, an anti-PD-L1 
antibody drug, showed long term protection against cancer with a response rate of 
6-17% [198]. By using breast cancer [233], melanoma, lung and colon mouse 
models [234] injected with cancer cells, it was shown that anti-PD-L1 treatment 
can provide a protection against tumors after the first injection and rechallenges of 
cancer cells.  
Taken together, this suggests that there are cancer antigens at an early 
stage, which can induce the specific anti-tumor immune response and anti-PDL1 
treatment is more beneficial at the early stage of tumor development.  
In humans, generally a single primary tumor develops that can metastasize.  
This contrasts to the mouse mammary tumor model in this study, where multiple 
tumors can arise as all the cells in the mammary gland can overexpress the 
oncogenic rat Her2.  Also in contrast, therapeutic treatment in humans with 
checkpoint inhibitors to date, has involved treatment up to 111 weeks [235]. We 
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choose to only treat 3 times after early diagnosis to determine if even a brief 
intervention was beneficial.  As shown in Figures 3 the early treatment had a 
significant inhibition on tumor growth late. We suspect that in the case of natural 
cases of tumors, the early treatment would be more efficacious.  It still may 
require a longer treatment regime than we tested to get better tumor inhibition.  
We note that the treatment was not started until the diagnosis was confirmed 4 
weeks later.  While a second monitoring is likely for human early detection and 
treatment scenarios, in the mouse model this would allow for significant tumor 
development. It should improve the protection if we treat the mice earlier.  
One thing worth noticed is that the average time of first palpable tumor in 
anti-PD-L1 treatment group was at 30.8 weeks, 35.8 weeks for three mice in non-
treatment group, and 33.8 weeks for all non-treatment mice we recorded. There 
was no significant difference between those three groups. This difference of 
average time of first palatable tumor by anti-PD-L1 treatment may be due to high 
variance in small sample size or may be caused by increasing TIL in tumor tissue 
resulting in increasing tumor size. Topalian et al. shown that in cancer patients 
after anti-PD-1 treatment the observed tumor size first increased after 2 months 
treatment then decreased at 4 months [198, 199].  
A combination of immune checkpoint blockades therapeutics has been 
tested in different mouse tumor models and shown better responses than the 
mono-blockade treatment [236, 237]. The clinical trial of combined nivolumab 
and ipilimumab treatment on human also showed better response than the mono-
treatment with a manageable safety profile [238]. The combined treatment 
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induced distinct immunologic changes in the patients [227]. Combination therapy 
may also improve the outcome for the cancer early treatment. Future studies will 
explore the effect of earlier, longer and combined treatment regimes.  
We propose that the work described here could be applied as a general 
plan for effectively eradicating cancer.  People would regularly send in a blood 
sample to be screened for the early signature of cancer. If a positive was detected 
the person would be rescreened soon after to confirm the diagnosis and assess the 
vector of the signature. A second positive diagnosis may be sufficient to initiate 
treatment. This decision could depend on factors discussed below. The response 
to the treatment could also be monitored by immunosignature. We believe the 
principle of all the elements of this scenario have been demonstrated in this work.  
One major concern relative to this scenario is the false positive rate.  If a 
tumor was misidentified, or more likely, was a tumor that would self-resolve or 
remain indolent, the concern is that false positive treatments would lead to 
unnecessary costs and increasing risk of side effects.  We believe that if the 
immunosignature protocol was both inexpensive and simple, it could substantially 
relieve the cost of false positives through retesting and assessment of the vector of 
change in tumor signatures. Studies to date indicate the immunosignature 
diagnostic can be both simple and inexpensive [225]. 
The other consideration is the cost and side-effects of the treatments.  If 
the systemic treatment with immune checkpoint inhibitors, or other systemic 
treatments, had little side effects, then it would not be a risk to treat positives, 
even though the eradicated tumor was benign or otherwise not life-threatening.  
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One, as yet to be tested possibility, is that treatment at an early stage would 
decrease the time of treatment and amount of therapeutic required, therefore 
reducing the risk and cost of treatment. Checkpoint inhibitor trials to date have 
been in cases of advanced tumors and have had significant occurrences of adverse 
effects [226]. 
Cost of treatment is a significant concern for the model depicted in Figure 
6.  Currently, the cost of a course of treatment with anti-PD-1 is reported to be 
over $12,500 a month [239].  If such a treatment were to be administered to kill 
any tumor arising the cost issue could be of major concern.  There are ~1.7M new 
cancer cases/year in the US.  At current checkpoint therapeutic treatment costs, it 
would require ~$200B/yr to treat all cancers. This is still less than the estimated 
current cost of treating cancer. Worldwide there are ~14M new cases/yr.   ~70% 
of the new cases are in the developing world.  Treatment of these cases at current 
costs would incur ~$1T/year which is approximately the current cost per year for 
cancer effects estimated in this sector (ACS/Livestrong report). Even though 
current costs of treatment might be justified, there is a clear incentive to develop 
less costly equivalent therapeutics.  We also point out that any drug, not only 
checkpoint inhibitors, that could be administered systemically and be effective 
could be used in this scenario.     
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APPENDIX A 
DETECTION OF OSTEOSARCOMA RECURRENCE IN CLINICAL CANINE 
SAMPLES BY IMMUNOSIGNATURE 
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AP1.1 Introduction 
AP1.1.1 Background of Osteosarcoma 
Osteosarcoma (OSA) is a malignant tumor of the bone [240]. It often 
starts in the shoulder, wrist, knee, cranium, spinal column, or ribs. Appendicular 
osteosarcoma, which is OSA of the limbs, accounts for 75-85% of all bone cancer 
in dogs. Bones with OSA are destroyed from the inside out. Intensive pain, 
obvious swelling-like lumps and lameness are evidence of tumor growth in OSA. 
Tumorous bones are easy to break and difficult to heal. OSA is also highly 
aggressive. Over 90% of clinical cases have micro-metastasized to the lungs and 
other organs by the time of diagnosis[241]. OSA is the most common canine bone 
tumor[242] and accounts for 85% of all primary canine bone tumors[243]. Bone 
tumors account for approximately 5% of all canine cancer. OSA has a high 
prevalence in middle-aged to elderly dogs (8 to 10 years) [244] with around 8,000 
cases diagnosed each year [240]. Large and giant breed dogs, including 
Rottweilers, Great Danes, Greyhounds, Saint Bernards and Doberman Pinschers 
[245-247], tend to develop OSA at younger ages [242]. Male dogs have a higher 
rate of OSA than female dogs [243].   
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AP1.1.2 Current Diagnosis and Treatment of OSA: 
Currently, radiographic imaging, age, gender and breed are the main 
diagnostic tools. Tissue biopsy is the gold standard to determine OSA. After the 
diagnosis of OSA, dogs can be treated with radiation therapy and analgesic 
medication (carprofen, aspririn, butorphanol and others). Surgery can also be 
performed. Limb-sparing techniques are adapted from human medicine and 
involve replacing the tumorous part of the bone with a bone graft. 
AP1.1.3 Recurrence of OSA  
Because of the high metastasis rate, many the dogs with OSA will already 
have micro- metastasis or recurrence after treatment of the primary tumor. 
Metastasis is the key factor that influence patient’s survival rate both in dog and 
human. In human cancer treatment, patients with localized cancer have better 
survival rates than those with metastatic disease [55]. According to American 
Cancer Society projected data for 2015, 61% of breast cancer cases are detected at 
a localized stage with a five-year relative survival rate of 99% [1]. However, 
when tumors spread to nearby lymph nodes or other tissues, the survival rate 
decreases to 85% [1]. If the breast cancer is in a late stage, in which tumors are 
found in lymph nodes around the collarbone or more distant, the survival rate falls 
to 25% [1]. The early detection of primary osteosarcoma and its recurrence will 
improve prognostic capability and treatment modality, relieve pain in dogs, and 
potentially extend their lives.  
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AP1.2 Result and Discussion 
AP1.2.1 Canine Osteosarcoma Clinical Sample Summary 
Dog samples were generously provided by Dr. Douglas H. Thamm from 
Colorado State University. Five dogs were serially collected for four time points. 
The four time points were labeled as Initial, A5, PTOR and OR, respectively. 
Sample IDs and dates for each time point are described below (Table AP1.1). The 
disease course interval is the difference of days between two time points. Initial 
was the time point of diagnosis before surgery. A5 was the time point of the fifth 
chemotherapy treatment, approximately ten weeks after diagnosis. PTOR was the 
time point of the last visit prior to relapse. OR was the time point of the visit at 
which the relapse was detected. Age-matched normal serum samples were are 
selected from clinically normal client-owned dogs. 
 
Table AP1. 1: Canine Osteosarcoma Clinical Sample Summary 
 
 
 
Sample
Sample ID 165155 171854 172133 168077 111098
Initial 1998/6/16 1999/5/27 1999/6/8 1998/10/29 1997/7/8
A5 1998/9/18 1999/8/19 1999/8/23 1999/1/6 1998/6/9
PTOR 1998/12/11 1999/9/20 2000/2/15 1999/3/19 1998/11/24
OR 1999/3/12 1999/9/27 2000/5/18 1999/6/10 1999/2/16
Disease course interval time (days)
Initial to A5 94 84 76 69 336
A5 to PTOR 84 32 176 72 168
PTOR to OR 91 7 93 83 84
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Blood samples from five dogs were serially collected for four time points. 
The four time points are labeled as Initial, A5, PTOR and OR, respectively. 
Sample IDs and dates for each time point have been described. The disease course 
interval is the difference of days between two time points. 
AP1.2.2 Correlation Analysis Of Overall Antibody Profile During OSA 
Progression  
For this time series study, it was interesting to know how the overall 
antibody profile changes at different time points by immunosignature technology. 
At each time point, the intensity of each peptide for the five samples was 
averaged. Pearson correlation, using all peptides between two time points, was 
calculated (Table AP1.2).   
 The highest correlation was 0.948 between OR (the time point of the visit 
at which the relapse was detected) and PTOR (the time point of the last visit prior 
to rela thatpse). This means the antibody response at PTOR was similar to that at 
OR and implies that the samples at PTOR might already have been at the 
recurrence stage and have a signature of recurrence. The lowest correlation was 
0.739, between PTOR and Normal. This implies that compared with the primary 
tumor, the recurrence was more distinguishable from normal.  
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Table AP1. 2: Correlation Analysis of Overall Antibody Profile 
 
The experiment was done by using the CIM 10K version-2 peptide arrays 
from Batch 324. Each sample was run with two to three replicates. Informative 
peptides were selected by comparing different stages with p value and fold change 
cutoff. P values were calculated by GeneSpring software using a two-tail T-test 
with FDR as a multiple comparison correction. The fold change of a peptide was 
calculated by using the average intensity of samples from one condition divided 
by the average intensity of samples from the other condition.   
Table AP1. 3: Distribution of Fold Change in Selected Peptides 
Fold is calculated by using the average intensity of each peptide at one time point 
divided by the other. Samples of recurrent disease include samples at both OR and 
PTOR.  
#: Numbers of peptides have different fold change between two conditions. An 
increase means that peptides have a certain fold change from one condition to the 
other, and vice versa for a decrease. 
 
Table AP1.3 lists the distribution of the numbers of selected peptides by 
fold change in three comparisons. I compared dog samples without canine cancers 
 
from normal to initial
Fold # increase decrease
1.5 115 99 16
2 20 18 2
2.5 4 3 1
3 2 1 1
4 2 1 1
5 0 0 0
from normal to recurrence
Fold # increase decrease
1.5 278 211 67
2 90 85 5
2.5 51 49 2
3 31 30 1
4 8 7 1
5 2 1 1
5.5 1 0 1
from normal to OR
Fold # increase decrease
1.5 197 170 27
2 71 67 4
2.5 35 34 1
3 18 17 1
4 1 0 1
6 1 0 1
6.5 0 0 1
All sample Initial A5 OR PTOR
Initial
A5 0.943
OR 0.95 0.942
PTOR 0.889 0.946 0.948
Normal 0.912 0.83 0.854 0.739
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(normal) with samples at initial diagnosis to find the immunosignature for 
primary OSA. As mentioned above in the introduction, OSA is highly aggressive, 
and micro-metastases may already be present when primary OSA is detected. The 
time difference between PTOR and OR was 71.6 days on average (ranging from 
7-93 days) for the five dogs. At the time of PTOR, the dogs could already have 
had micro-recurrent tumors. By combining samples at PTOR and OR together, 
with label “recurrent,” this could cover all stages of recurrent OSA 
comprehensively. By comparing normal with recurrent samples, I could 
investigate the immunosignature of recurrent OSA. OR was the time point when a 
relapse was determined clinically. By comparing OR with normal samples, I 
could investigate the immunosignature of recurrent OSA for that specific time 
point. 
The result shows that most selected peptides had 1.5- to two-fold change. 
A few had a greater than four-fold change. Most selected peptides were increased, 
with fewer than 20% decreased, on average. The number of decreased peptides 
dropped faster than the increased ones with the increase of fold change. These 
data show that we could find immunosignatures to distinguish primary OSA and 
recurrent OSA from healthy controls. They also show that most of the selected 
peptides had higher intensity levels in dogs with OSA compared with health 
controls.  
AP1.2.3 Comparison of Immunosignature at Multiple Time Points  
After finding informative peptides for each time point, I wanted to ask 
how the intensities for those peptides changed along tumor development. This 
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could reveal the role of tumor-related antibodies during the disease progression of 
OSA.  
I first selected two peptide sets: 1) the 94 overlapped peptides between 
115 peptides of primary OSA and 278 for recurrent OSA at both OR and PTOR; 
and 2) the 86 overlapped peptides between 115 peptides of primary OSA and 197 
for recurrent OSA at OR. 85 peptides of the 86-peptides set were shared in the 94-
peptide set. 
  
Figure AP1. 1: Proportion of Overlapped Peptides Shared Among Different Time 
Points 
Intensity level of the overlapped peptides are plotted against each time point. 
 
21 184
Primary Recurrence
OR+PTOR
94 29 111
Primary Recurrence
OR
86
overlapped 94 overlapped 86
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Table AP1. 4: Proportion of Overlapped Peptides Shared Among Different Time 
Points 
 
From the Figure AP1.1, the intensity of the majority of the overlapped 
peptides intensity increased from Initial to A5 and to PTOR, but decreased in OR. 
From the Table AP1.4, the number of significant peptides overlapped between 
primary OSA and recurrent OSA was 74.8%- 81.7% in the 115-peptide set and 
decreased to 43.7% - 47.7%. 
These data mean that different antibodies were dominant at different time 
points. This might be due to the immunoediting process between OSA and the 
immune system in dogs. Antigens that presented in the primary OSA disappeared 
due to high immunogenicity. After the tumor developed, more neo-antigen may 
have appeared and triggered different antibody responses at the recurrent stage. 
 
Figure AP1. 2: Intensity Plot of Significant Peptides between Primary and 
Recurrent OSA 
Percentage of the overlap peptides in each set
Overlap Initial(115) Recurrence(278) OR(197)
94 81.7% 33.8% 47.7%
86 74.8% 30.9% 43.7%
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In order to further test whether there was a difference between primary 
tumor and recurrent tumor, I asked how many peptides were statistically 
significant between primary and recurrent by comparing these two time points. 35 
peptides were selected. As Figure AP1.2 shows, most of them decrease from 
primary to recurrent. The PCA result on the 35 peptides shows cluster of primary 
samples and recurrent samples by each time point. These show that primary OSA 
differed from recurrent OSA in terms of their immune response to tumor antigens.  
AP1.2.4 Conclusion and Future Direction 
I recognize the limited sample size for this experiment, and I don’t have 
further validation of the discovered immunosignature. Some of the selected 
peptides may have been due to randomness. The signature discovered may not 
well represent different breeds of dogs with osteosarcoma. However, in this study, 
I have used multiple comparison methods to reduce the possibility of randomness 
and carefully test each sample. This study could still be beneficial to studying 
osteosarcoma.  
With the development of OSA, the overall antibody profiles changes 
substantially. Different immunosignatures were found for primary OSA and 
recurrent OSA. The significant peptides are increased from normal controls to 
tumor samples, showing increasing anti-tumor immune response. The difference 
between primary OSA and recurrent OSA exists. Most significant peptides 
decrease from primary OSA to its recurrence. Based on the data, the selected 
peptides can be grouped into the following categories: Intensities were high in 
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normal and low in initial. This may be due to the immunosuppression or Treg by 
the primary tumor. Intensities increased after treatment: suppression was relieved 
and IS increased in the recurrence. Intensities decreased at late recurrence: the 
recurrent tumor seemed to suppress these peptides but not significantly. It 
behaved differently from the primary tumor. This may imply that the immune 
suppression from primary and recurrent tumors was different. 
In order to get a more solid immunosignature of primary and recurrent 
osteosarcoma, more dog samples with initial, A5, PTOR, OR time points are 
needed. Current PTOR is the time point before relapse is detected, with an 
average of 71.6 days before recurrence. In order to address the early detection of 
OSA recurrence, it will be better to get a time point that precedes recurrence 
detection by a longer period. It will be better to have samples for which the 
interval between “initial to A5” and “PTOR to OR” is long enough to have more 
distinguished stages. 
AP1.3 Methods 
AP1.3.1 Sample Summary 
Dr. Douglas H. Thamm from Colorado State University generously 
provided five canine osteosarcoma clinical samples. The breeds of the five canine 
patients are Borzoi, Labrador retriever, golden retriever, and mix breeds. Each 
dog had been confirmed with osteosarcoma histologically or cytologically. Sera 
from each dog were serially collected for four time points. The four time points 
were labeled as Initial, A5, PTOR and OR respectively. Initial is the time point of 
diagnosis before surgery. A5 is the time point of firth chemotherapy treatment, 
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approximately ten weeks after diagnosis. PTOR is the time point of the last visit 
prior to relapse. OR is the time point of the visit at which relapse was detected. 
Sera were collected and stored at -80°C through all collections. 
Chemotherapy-naïve primary tumor samples were selected from the 
Colorado State University Animal Cancer Center's tissue archive based on the 
criteria that the patient had undergone surgical amputation followed by 
chemotherapy with doxorubicin and/or a platinum-based drug. Doxorubicin 
(Adriamycin) was given every two weeks for five treatments. 
AP1.3.2 Binding of Sera to the Peptide Microarrays and Microarray Data 
Processing 
CIM standard clinical protocol with four steps was used. Detailed methods 
can be found in Chapter 2 and 3.  
AP1.3.3 Statistical Analysis 
Statistical analysis of microarray data was done with Gene- Spring 7.3.1 
(Agilent, Inc., Palo Alto, CA) by importing image-processed data from GenePix 
Pro 6.0 (Axon Instruments, Union City, CA). Calculations based on the GenePix-
prepared gpr text files were done on the median signal intensity per spot. Poor 
quality spots were excluded from analysis by flagging as “absent” upon visual 
inspection. Prior to analysis, each array was normalized to the 50th percentile to 
eliminate array-to-array variation, and signal intensities of less than 0.01 were set 
to 0.01. Values from replicate arrays were averaged and used in the analysis. P-
values were corrected for multiple testing by the Benjamin-Hochberg false 
discovery rate method in Genespring GX 7.3 software (Agilent Technologies, 
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Palo Alto, CA). The Welch t test was used in GeneSpring to select significant 
peptides with p<0.05 between two groups. 
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APPENDIX B 
CHARACTERIZATION OF ANTIBODY PROFILE DURING CANCER 
DEVELOPMENT 
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AP 2.1 Quantitative Characterization Of Antibody Profiles During Tumor 
Development 
AP2.1.1 Introduction 
Immunosignatures allow us to study the overall antibody profile of a 
sample. We can quantitatively evaluate the distribution of overall antibodies at a 
certain time point in a disease to potentially reveal its internal patterns. A 
quantitatively method to measure statistical dispersion of antibodies can indirectly 
show antigen heterogeneity. This can help researchers to understand the 
interaction between the immune system and cancer.  
Different statistical parameters are available to characterize the 
distribution of information with a single quantitative value. With the increasing 
popularity of mobile and wearable devices, customers can collect data about their 
health easily. A simple visualization of major biological information in our bodies 
will make it possible for everyone monitor their health. In Dr. Kurt Whittemore’s 
dissertation research, he used AbStat as a tool to characterize the antibody profile 
of a patient through immunosignature technology. The current work is a 
collaboration with Dr. Whittemore and uses his AbStat algorithm to calculate 
entropy, coefficient of variation, kurtosis, skew, and dynamic range [248-251].  
Entropy is a measurement of the homogeneity of a frequency distribution. 
If all information in the distribution is ordered (with homogeneous value), its 
entropy decreases. The minimum value is zero when all values in that distribution 
are identical. The value increases when the distribution is more heterogeneous. 
The maximum entropy is achieved when values of every element are different 
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from each other. Kurtosis measures the peakedness of a frequency distribution, 
with higher values indicating a sharper peak. Skewness measures symmetry: a 
larger absolute amount of skewness indicates a more asymmetric distribution, 
which means that values in that distribution lean to one side of the mean. 
Dynamic range is the ratio of the value of 95% intensity to the value of 5% 
intensity. A high dynamic range indicates a wider range of distribution. The 
coefficient of variation is the ratio of the standard deviation to the mean. A high 
coefficient of variation indicates a high degree of dispersion.  
We performed a time series study to characterize the overall antibody 
profile during tumor development, using two transgenic mice and two wild type 
controls (Figure AP2.1, Figure AP2.2). By doing this, we hope to find some 
interesting general pattern between the immune system and cancer. 
AP2.1.2: Result and Discussion 
Sera were collected every two weeks for two transgenic mice and two age-
matched wild type mice (Table AP2.1, Table AP2.2). Sera from these samples 
were run on the CIM Version-2 arrays using a standard CIM clinical protocol 
with one replicate at each time point. We used one replicate because the 
abundance of continuous time points allowed us to get a good representation of 
the antibody profile during tumor development with one replicate. Slides were 
randomly chosen from all available slides in the same batch of slides by “sample” 
function in R. Arrays, and samples were also randomly assigned to different 
positions on the Tecan. 
 
 134 
 
Figure AP2. 1: Summary of Mice Samples 
Sixteen time points of Tg8-1-1, twelve time points of Tg8-3-9 and WT1-3, and 
eight time points for wild type mice WT2-3 were used. 
 
 
Figure AP2. 2: Tumor growth Curve for Tg8_1-1 and Tg8_3-9 Transgenic Mice 
 
Entropy, kurtosis, skewness, dynamic range, and CV were calculated for 
two transgenic mice and two wild type controls at multiple time points during 
tumor development (Figure AP2.3, AP2.4). The results show that the value of 
kurtosis, skewness, dynamic range, and CV were similar and correlated between 
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transgenic mice and control mice. The chaotic pattern of these parameters showed 
dynamic changes occurring in the antibody repertoire during mouse development 
(Table AP2.1). These changes might be the result of the aging process instead of 
tumor development, as there was no significant difference between the transgenic 
mice and the wild type controls for these parameters.  
Figure AP2. 3: AbStat Time Course for Transgenic Tg8-1-1 and Wild Type WT2-
3 Mice 
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Figure AP2. 4: AbStat Time Course for Transgenic Tg8-3-9 and Wild Type WT1-
3 Mice 
 
 
Table AP2. 1: Coefficient of Variance of Entropy, Kurtosis, Skewness and 
Dynamic Range of All Time Points for Each Mouse 
 
Only entropy showed some level of difference between the transgenic 
samples that developed tumor later and the wild type controls (Figure AP2.5). In 
WT 2-3, the entropy for the wild type controls was linear increasing with less 
variance, compared with Tg8-1-1. The entropy for Tg8-1-1 fluctuated along 
tumor development with significant variance. However, this pattern was not 
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evident in the wild type mouse. Dr. Kurt Whittemore’s study showed a positive 
correlation between entropy and age. The constant increase in wild-type mice may 
be the result of the aging process, when more antibodies were produced during 
their lifetimes. However, in the transgenic mice, entropy of the antibody 
repertoire was chaotic instead of showing a constant increase. This might have 
been the result of an immunoediting process between tumor and immune system. 
Different antibodies were produced to target tumors at different development 
stages. The immune system might have produced a large amount of antibodies 
when antigens were highly immunogenic in tumor cells and then decreased 
antibody production because of mutations in those antigens that made them not 
immunogenic. This distinct difference of entropy in transgenic mice and wild-
type mice may be an indicator for tumor development.  
Figure AP2. 5: Entropy Time Course for Transgenic and Wild Type Mice 
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the antibody repertoire during tumor development. A time series study of cancer 
was first conducted in the immunosignature platform to discover hidden patterns 
over time. The results implied that entropy could be a useful parameter to evaluate 
tumor development and to measure statistical dispersion of antibodies and 
indirectly show antigen heterogeneity.  
AP2.2 A Time Series Study of Antibody Profile Along Tumor Development 
AP2.2.1 Introduction 
Although immunoediting theory suggests that tumor cells present different 
antigens along tumor development, few studies have investigated the dynamic 
process of the immune system during tumor development. Immunosignature can 
reflect different antibody profiles at different stages. It provides us an opportunity 
to evaluate the antigen heterogeneity along tumor development by analyzing 
immunosignature in a time series study.  
Compared with static comparisons, a time series study of biomarkers has 
the advantage of improving the performance of diagnostic methods. The pitfall of 
current biomarkers in bigger populations is that there is substantial heterogeneity 
even in populations with similar genetic backgrounds. Although common profiles 
can be found and an absolute cutoff can be drawn, the results may not be relevant 
to each individual. Therefore, dynamic measurements that allow the assessment of 
within-patient expression changes will be more useful [56]. The recent study on 
continuous monitoring of multiple omics by Rui Chen and colleagues showed the 
promise of self-monitoring in personalized medicine and diagnosis [252]. 
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The method for analyzing multiple time points of a feature falls under time 
series analysis. Time series studies have a number of advantages: they can use the 
time series structure in the data; can increase the accuracy of prediction; and can 
capture information about features with transient expression changes. These are 
not possible in static studies that compare only two populations at a single time 
point.  
In this study, an individual dynamic monitoring of the antibodyome was 
conducted in a murine breast cancer model. 
AP2.2.2 Result and Discussion 
In order to study the time serial pattern of the antibodyome, we used 
serum samples from the same individual at multiple time points. In fields in which 
time series analyses is widely used, such as economics, astronomy, physics and 
industrial engineering, time series data normally include more than 30 time points. 
However, in biology, such an extended sequence of samples is rarely accessible. 
For this study, I had a time series serum collection for FVB/N neuN transgenic 
mice and FVB/N wild-type mice with more than ten time points for each mouse. 
Serum for each mouse was collected every two weeks, from mice aged 5-10 
weeks to 40-45 weeks, which covered the complete tumor development stages.  
In this study, I chose two transgenic mice (Tg8-1-1, Tg8-3-9) and two 
wild-type mice (WT1-3, WT2-3) (Table AP2.2, Table AP2.3). Sixteen time points 
of Tg8-1-1, twelve time points of Tg8-3-9 and WT1-3, and eight time points for 
wild type mice WT2-3 were used. The samples used in this study were the same 
samples run in the AP2.1 section. The interval was the weeks between two time 
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points. It should be noted that in order to have a better result in time series 
analysis, a constant interval is important. In Tg8-1-1, the average interval is 
2.02±0.37 weeks. In Tg8-3-9, the average interval is 1.98±0.4 weeks.  
 
Table AP2. 2: Sample Information for Tg8-1-1 and WT2-3 
 
Tg8-1-1 WT2-3
Tumor size (mm3) Age (wks) Window (wks) Interval (wks) Age (wks)
15.1 -18 2.3 15.3
17.4 -15.7 1.9
19.3 -13.8 2.1 19.1
21.4 -11.7 2.7
24.1 -9 1.2 24.1
25.3 -7.8 2.1
27.4 -5.7 2
29.4 -3.7 2.2 29.1
31.6 -1.5 1.5
0.5(1) 33.1 0 2.5 33.1
89.43(2) 35.6 2.5 1.8
261.71(2) 37.4 4.3 1.7 37.4
423.64(2) 39.1 6 2
711.49(3) 41.1 8 2.2 41.3
1626.01(4) 43.3 10.2 2.1
3326.36(4) 45.4 12.3 45.4
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Table AP2. 3: Sample Information for Tg8-3-9 and WT1-3 
 
Autocorrelation function (ACF) is a standard method to analyze time 
series data. A feature with time series patterns is autocorrelated, and the Durbin-
Watson test can calculate and test its significance (Figure AP2.6). The Durbin-
Watson Test in the R package was used to calculate the significance of ACF with 
a cutoff of p value at 0.05. Peptides passing the test should have autocorrelation 
structure instead of randomness.  
 
 
 
 
 
 
 
Tg8_3-9 WT1-3
Tumor size (mm3) Age (wks) Window (wks) Interval (wks) Age (wks)
0 19.3 -12.3 2.1 17.3
0 21.4 -10.2 2.7 19.1
0 24.1 -7.5 1.2 21.1
0 25.3 -6.3 2.1 24.1
0 27.4 -4.2 2 27.3
0 29.4 -2.2 2.2 29.1
35.93(1) 31.6 0 1.5 31.3
165.38(1) 33.1 1.5 2.5 33.1
493.32(1) 35.6 4 1.8 35.1
1105.01（2） 37.4 5.8 1.7 37.4
2215.85（2） 39.1 7.5 2 39.1
2932.92（2） 41.1 9.5 41.3
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Figure AP2. 6: Concept of Autocorrelation function (ACF) and Durbin-Watson 
Test 
 
249 peptides in Tg8-1-1 and 849 peptides in Tg8-3-9 passed Durbin-the 
Watson test with p value less than 0.05. These peptides showed an autocorrelated 
structure. Self-Organizing Map was used to cluster the significant peptides into 
Tg8-1-1 and Tg8-3-9 and to reveal potential patterns (Figure AP2.7). Several 
clusters showed a correlated trend between signal intensity and tumor 
development, although patterns were different for each individual. Tg8-1-1 had 
increased peptides around a tumor-initiated point, while Tg-3-9 only had 
decreased ones. This pattern could be a representation of the immunoediting 
process in the mouse immune system. 
 
Autocorrelation function (ACF)
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Figure AP2. 7: Self-Organizing Map to cluster 249 autocorrelated peptides in 
Tg8-3-6.  
Setting for SOM in GeneSpring are Rows 3, Columns 3, Iterations 10000, Radius 
4.0. 
 
 
Tg8-1_ACF_249: Rows 3, Columns 3, Iterations 10000, Radius 4.0. 
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Figure AP2. 8: Self-Organizing Map to cluster 849 autocorrelated peptides in 
Tg8-3-6. Setting for SOM in GeneSpring are Rows 3, Columns 3, Iterations 
10000, Radius 4.0. 
 
One cluster of the 249 peptides by K-means included a cluster of 24 
peptides (Figure AP2.9). The intensity of these peptides increased 5.7 weeks 
before the first tumor occurred and decreased later. The intensity changes of these 
peptides may be caused by the primary tumor. In order to show that the changes 
are tumor-related, the same 24 peptides were also plotted in the age-matched 
wild-type mice. The autocorrelated pattern appeared only in the transgenic mice 
with the development of tumors but not in the wild-type controls, which indicated 
its tumor specificity. The changing pattern implies that tumor antigens may have 
appeared early, before the primary tumor triggered a strong immune response, and 
that those antigens disappeared when the tumor matured.  
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Figure AP2. 9: Intensity of a cluster of 24 autocorrelated peptides correlated with 
tumor development 
The orange arrow is the time point for first primary tumor.  
 
In this study, an individual dynamic monitoring of antibodyome was 
conducted in a murine breast cancer model. Autocorrelation function was 
calculated for each peptide in two transgenic mice and two wild-type mice. The 
Durbin-Watson test was used to find significant peptides with autocorrelation 
structure. Selected autocorrelated peptides showed dynamic and tumor-specific 
changes with tumor development. The pattern of changes can be tracked back five 
weeks before the tumor was palpable. Although this study used only four mice 
and the results have not been repeated, the results might attract the interest of 
other researchers in this field. The method used in this study can also be applied 
to genomic, transcriptomic, proteomic, and metabolomic data. 
 
  
Tg WT
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AP2.3 Robustness of immunosignature  
AP2.3.1 Introduction 
A good, robust biomarker should have low variance in a population, even 
when that population is diverse. On the one hand, since many biomarkers have 
high variance in both healthy and diseased populations, they are likely to fail in 
clinical trials, as they cannot differentiate the overlap between the healthy and 
diseased populations. This kind of biomarkers I called limited biomarkers. They 
will lead to high false-positive rate. A robust biomarker, on the other hand, should 
have low variance in both healthy and diseased populations (Figure AP2.10) so 
that a sample can be classified as either disease-positive or disease-negative with 
high accuracy. We use correlation to measure the heterogeneity in a population. If 
the correlation among samples in a population is high, that means that there is low 
variance in that population. 
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Figure AP2. 10: Concept of Robustness in immunosignature 
 
AP2.3.2 Result and discussion: 
Table AP2. 4: Sample Information for Robustness Test 
 
In this study, serum samples from four transgenic (Tg) and eight age-
matched wild-type (WT) control mice at a time point before the first breast tumor 
was detected were run in CIM V2 arrays using the standard CIM clinical protocol 
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Treatment Control
Tg-1_31 WT Cage1-1_19 WT Cage2-1_17
Tg-10_16.6 WT Cage1-2_17 WT Cage2-2_19
Tg-11_19.4 WT Cage1-3_19 WT Cage2-3_17
Tg-8_16.8 WT Cage1-4_17 WT Cage2-4_19
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(Table AP2.4). Sixty-seven peptides were significant by t-test (p<0.05), with a 
1.3-fold change as the cutoff. The selected peptides were specific 
immunosignatures for breast cancer at two weeks before the first tumor. Here, we 
wanted to test whether these peptides were robust or not.  
The correlations of 67 peptides in either the transgenic group or the 
control group were high and had a low variance (Figure AP2.11). These were 
called in-group correlations. The calculated correlation between one transgenic 
sample and one wild-type sample and all possible combinations were called 
between-group correlations. The correlation of 67 peptides was lower than the in-
group correlation and had a much wider range. This showed that the selected 67 
peptides had lower variance in in-group correlations and had higher variance in 
between-group correlations (p<0.01 between among and WT). 
Figure AP2. 11: Correlation of selected peptides in transgenic (Tg) and wild-type 
(WT) control mice.  
Correlations of 67 peptides in any two samples of Tg group are label with “Tg”, 
same as “WT”. Correlations between one transgenic sample and one wild-type 
sample and all possible combinations are labelled with “among”.  
 
among vs Tg P = 0.14
among vs WT P < 0.01
Tg vs WT P > 0.05
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In order to show that the difference between in-group and between-group 
correlations were not due to internal array bias, I calculated the correlations for 
both using all peptides on the 10K array (Figure AP2.12). This should reflect the 
overall antibody profiles of samples. The result was that in-group and between-
group correlations were at around same level, and their variance was not as great 
as in the correlation of the 67 selected peptides. 
Figure AP2. 12: Correlation of all peptides on the 10K array 
 
In sum, I tested the robustness of selected peptides and showed that 
robustness could be a criterion for evaluating the performance of an 
immunosignature.  
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APPENDIX C PERMISSIONS 
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Permissions have been obtained to reprint copyrighted material.  
American Cancer Society has granted permission automatically to use 
Figure 1. 1 Biology of Breast Tissue and Figure 1. 2: Illustration of Mammogram 
and MRI and Figure 1. 3: Five-year Relative Survival Rates (%) by Stage in US. 
Molecular & Cellular Proteomics has granted permission automatically to 
use Figure 1. 4: Distribution of Human Plasma Protein. 
Figure 1. 6: Introduction of CTLA-4 and PD-1 Treatment has obtained 
permission for Elsevier with license number 3654470549052. 
Use of Figure 1. 7: Biology and Mechanism of Anti-PD-L1 Antibody 
Treatment has been approved by Leann Sandifar, Vice President – Operations, 
from Patient Resource LCC on June 11th.  
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BIO SKETCH 
I grew up surrounded by outstanding healthcare professionals and 
biomedical researchers. As a child, I was curious about the fancy equipment that 
doctors used to perform surgery and amazed by how easily the drugs a doctor 
prescribed could cure a patient’s disease. Seeing patients relieved of their pain 
and the happiness of parents when their child was cured made me feel that doing 
something that could improve people’s health would be a meaningful way to 
spend my life. I chose biotechnology as my undergraduate major at Wuhan 
University in China. The concept that, in the future, a person’s health condition 
could be monitored conveniently and that diseases could be detected before 
symptoms occur became clear to me. I realized that early diagnosis and 
prevention were more crucial than treatment at the late stage of disease.  Since 
that time, I have been interested in all kinds of new technologies to diagnose a 
disease. I came to ASU because it was one of only a few universities that have 
many professors focusing on developing diagnostic tools for human diseases. My 
work with Dr. Johnston is to find new strategies to diagnose breast cancer early 
and to improve cancer outcomes through novel treatment. It has been an amazing 
journey, and I feel sincerely grateful to Dr. Johnston and ASU for giving me this 
opportunity. Upon graduation, I plan to pursue a career in building novel 
technology to improve people’s health. 
